2016 EXPRESSIONS



Krupanidhi College of Pharmacy

Agni
Films

PRINT ADS | AD FILMS | CANDID FILMS | CSR PROJECTS

CORPORATE FILMS | CORPORATE SHORT FILMS | TV BROADCAST

PRESS RELEASE | BRANDING

OUR BRAND PARTNERS

OUR MEDIA PARTNERS

WWW.AGNIFILMS.COM

+971 988 618 3323 / +971 9060 12 4041 contact@agnifilms.com

"We carve stones, we just don't polish them.
We make monuments out of them."

Prof. Suresh Nagpal
Founder Chairman - Krupanidhi Educational Trust



Fostering Pharmaceutical Excellence

Attaining the highest level of pharmaceutical professional capabilities has been our credo since 1985. At KCP we are committed to foster pharmaceutical excellence.

Excellence demands passion, practice, resolve and tenacity. KCP fosters a newer generation of pharmacists to pursue excellence in all the facets of this noble profession.

2016 EXPRESSIONS

In pursuit of Excellence

Krupanidhi College of Pharmacy

No-12/1, Chikkabellandur, Carmelaram Post, Varthur Hobli, Bangalore - 560035
(NAAC Accredited & An ISO 9001 : 2008 Certified Institution)
Recognized by the Govt.of Karnataka, Approved by Pharmacy Council of India,
AICTE, New Delhi & Affiliated to
Rajiv Gandhi University of Health Sciences, Bangalore.

Rajiv Gandhi University of Health Sciences, Karnataka

Rank Holders

Congratulations and Good Luck

M PHARM TOPPERS MAY 2015

Sakshi Sharma
M.Pharm (Ph.Ceutics)
4th Rank

Hima Sai Krishna
M.Pharm (Q.A)
5th Rank

Ganga Madhavi G
M.Pharm (Q.A)
9th Rank

Hansa Gupta
M.Pharm (Ph.Cology)
7th Rank

Neelima Dileep
M.Pharm (Ph.Cology)
1st Rank

PHARM D TOPPERS MAY 2015

Arya Gigi
5th Rank

Ahmadi Naaz
9th Rank

Merlin T S
10th Rank

B PHARM TOPPER MAY 2015

Rina Pokhrel
4th Rank

PHARM D (PB) TOPPERS MAY 2014-15

Nikitha
1st Rank

Daghari Zakieh Jasem
2nd Rank

Sumi Jose
6th Rank

Arpan Dutta Roy
9th Rank

Seyed Sam Banisadr
10th Rank

2016

EXPRESSIONS

Commendations

MESSAGE

His Excellency

Shri Vajubhai Vala

Hon'ble Governor of Karnataka

I am happy to know that Krupanidhi College of Pharmacy, Varthur Hobli, Bangalore, is bringing out college magazine 'Expressions' which provides the students a forum to express their ideas, thoughts and their experiences during the course of their stay in the Institution. I understand that this institution is accreditated and has a credit of securing 350 ranks at university, Board and college level since 1985.

I send my felicitations and best wishes to the organizers, editorial team and also for a grand success of the event.

sd/-
Shri Vajubhai Vala

MESSAGE

Shri Jagat Prakash Nadda
Minister of Health & Family Welfare
Government of India

My heartiest congratulations to Krupanidhi College of Pharmacy for Brining out its annual magazine 'Expressions - 2016'.

One of the leading pharmacy colleges in Karnataka, Krupanidhi College not only has one of the most advanced infrastructures but its faculty comprises of the industry's best practitioners.

I would like to extend felicitations to Krupanidhi College of Pharmacy and its dedicated team for their years of service and success. I wish all the best to the institute. the faculty, the staff and students who have contributed significantly to the growth of the Institute as well as the pharmaceutical industry.

Shri Jagat Prakash Nadda

MESSAGE

Prof. B. Suresh Ph.D., D.Sc.,
President
Pharmacy Council of India, New Delhi

I am delighted to write this message for the "Expressions" College Magazine being published by Krupanidhi College of Pharmacy, Bengaluru.

On this occasion, I congratulate the Principal, Faculty, staff and students for bringing out "Expression" and convey my good wished and hope that this edition of the college magazine would be meaningful and memorable.

with best wishes

Dr. B. Suresh
President

MESSAGE

Mrs. Archana Mudgal
Registrar-cum-Secretary
Pharmacy Council of India, New Delhi

I on behalf of Pharmacy Council of India extend greeting and good wishes for the success of your college magazine "Expressions".

Mrs. Archana Mudgal
Registrar-cum-Secretary

MESSAGE

Dr. K. S. Ravindranath
M.D., D.M., D.N.B. (Cardio)
Vice-Chancellor
Rajiv Gandhi University of Health Sciences, Karnataka
Bangalore

It gives me pleasure to learn that Krupanidhi College of Pharmacy, Bengaluru is celebrating its annual day. A college magazine is also scheduled to be released to commemorate this occasion. The college has a tradition of observing the annual day and providing platform for the students to demonstrate their co-curricular talents.

The annual college magazine - 'Expressions' is being released with regularity for the past many years. I hope that the magazine will provide useful articles and valuable information to its readers.

I wish all the students of this institute a great future as pharmacy professionals and wish success for your annual day.

Dr. K. S. Ravindranath
Vice-Chancellor

MESSAGE

Shri Nagaraja KAS (STS)
Registrar
Rajiv Gandhi University of Health Sciences

I am happy to learn that the Krupanidhi College of Pharmacy, Bengaluru is celebrating its annual day and will also release a souvenir to mark this occasion. This institution is managed by a group of dedicated professionals and committed teachers. This institution is in existence since 1985 and has been pioneering quality pharmacy education in our state.

As part of the annual day celebrations, the college magazine – 'Expressions' will also be released. I am sure that the magazine will have many useful articles and valuable information

I wish all the students of this institute a great future as pharmacy professionals and wish success for your annual day.

sd/-
Shri Nagaraja
Registrar

MESSAGE

Shri Rao V. S. V. Vadlamudi, PhD,
President, Indian Pharmaceutical Association (IPA)
raovsvv@ipapharma.org
Director, St. Peter's Institute of Pharmaceutical Sciences,
Hanamkonda, Warangal, Telangana State
rao.vadlamudi@gmail.com

I am delighted to note that the Krupanidhi College of Pharmacy is coming up with the College Magazine "Expressions" scheduled to be released in the month of May 2016. The Krupanidhi College of Pharmacy established in 1985, has grown to be recognised as one of the leading institutions in the country imparting quality pharmacy education to a very successful of crop of students who have brought many laurels to the institution. The uniqueness of this institution is mainly due to the fact that the Krupanidhi group of Institutions have adopted and nurtured the gurukulam system of education.

The college magazine 'Expressions', a brain child of the alumni of this institute provides a platform fo the students to express their thoughts, innovative and unique ideas and also helps to bring out the hidden talents in the students. I am sure this magazine would be instrumental to develop the writing skills of students, which is now recoginsed as an important attribute of highly successful students. I am quite confident that this new edition of 'Expressions" scheduled to be released in May 2016, is fully packed with highly educative and entertaining articles written by the college alumni, current sudents, faculty and experts of the pharmacy profession. I wish the magazine and the institute a huge success.

V.V.S. Veerabhadra Rao

Shri Rao V. S. V. Vadlamudi, Ph. D.
President, IPA
Hyderabad

MESSAGE

Shri Raghurama Bhandary
Drugs Controller
for The State of Karnataka

I am extremely happy to know that the Krupanidhi College of Pharmacy, Bangalore is bringing out a magazine "Expressions". The Magazine, I am sure, will be informative and resourceful & will provide excellent opportunities to the students as well as the Pharmacy profession to brighten their academic, professional skills and focus their attention for further growth and development of Pharmacy Profession. I am also glad to know that your college is NAAC accreditated and has secured more ranks.

I congratulate & convey my good wishes to the Principal, students, faculty and staff of Krupanidhi College of Pharmacy, Bangalore for their efforts in bringing out the magazine.

Shri Raghurama Bhandary
Drugs Controller

MESSAGE

Mrs. Dharani
CEO
MVJ Medical College & Research Hospital, Hoskote

I am proud to be the part of an inspiring journey called "Expressions-2016". Krupanidhi College of Pharmacy has grown from a humble beginning to Himalayan heights in its long journey of 31 years from the inception in achieving academic excellence by securing 350 ranks at University, Board & College level since 1985.

The Management of Krupanidhi College has been working hard, year after year in providing holistic & social responsible professionals through its group of educational institutions and I appreciate the consistent growth of your College in producing brilliant young students from your institutions. I wish them all success in bringing out this beautiful magazine "Expressions – 2016". As the CEO of MVJ Medical College & Research Hospital I continue to extend the academic support to the students of Krupanidhi College of Pharmacy to excel by rigorous training & exposure to clinical materials available abundantly in our Medical College Hospital. Wishing them all the success in their future endevours.

sd/-
Mrs. Dharani
CEO, MVJ

MESSAGE

Prof. Suresh Nagpal
Chairman
Krupanidhi Education Trust, Bangalore

Important Phases of Education

Primary education: It is the first stage of compulsory education. It is preceded by pre-school or nursery education and is followed by secondary education. In most countries, it is compulsory for children to receive primary education, though in many jurisdictions it is permissible for parents to provide it.

The major goals of primary education are achieving basic literacy and numeracy amongst all pupils, as well as establishing foundations in science, mathematics, geography, history and other social sciences. The relative priority of various areas, and the methods used to teach them, are an area of considerable political debate.

Typically, primary education is provided in schools, where the child will stay in steadily advancing classes until they complete it and move on to high school/secondary school. Children are usually placed in classes with one teacher who will be primarily responsible for their education and welfare for that year. This teacher may be assisted to varying degrees by specialist teachers in certain subject area often music or physical education. The continuity with a single teacher and the opportunity to build up a close relationship with the class is a notable feature of the primary education system.

The National Council of Educational Research and Training (NCERT) is the apex body for school education in India. The NCERT provides support and technical assistance to a number of schools in India and oversees many aspects of enforcement of education policies. In India, the various bodies governing school education system are:

- The state government boards, in which the majority of Indian children are enrolled.
- The Central Board of Secondary Education (CBSE) board.
- The Council for the Indian School Certificate Examinations (CISCE) board.
- The National Institute of Open Schooling.

- International schools affiliated to the International Baccalaureate Programme and/or the Cambridge International Examinations.
- Islamic Madrasah schools, whose boards are controlled by local state governments, or autonomous, or affiliated with Darul Uloom Deoband.
- Autonomous schools like Woodstock School, Auroville, Patha Bhavan and Ananda Marga Gurukula.

School teaching in India consists of 12 grade (classes) levels. These are:

- Kindergarten: nursery - 3 years, Lower Kindergarten (LKG) -4 years, Upper Kindergarten (UKG) - 5 years
- 1st class: 6 years
- 2nd class: 7 years
- 3rd class: 8 years
- 4th class: 9 years
- 5th class: 10 years
- 6th class: 11 years
- 7th class: 12 years
- 8th class: 13 years
- 9th class: 14 years
- 10th class: 15 years
- 11th class: 16 years
- 12th class: 17 years

However, due to shortage of resources and lack of political will, this system suffers from massive gaps including high pupil to teacher ratios, shortage of infrastructure and poor levels of teacher training. Education has also been made free for children for 6 to 14 years of age or up to class VIII under the Right of Children to Free and Compulsory Education Act 2009. There have been several efforts to enhance quality made by the government. The District Education Revitalization Programme (DERP) was launched in 1994 with an aim to universalize primary education in India by reforming and vitalizing the existing primary education system. 85% of the DERP was funded by the central government and the remaining 15 percent was funded by the states. The DERP, which had opened 160000 new schools including 84000 alternative education schools delivering alternative education to approximately 3.5 million children, was also supported by UNICEF and other international programmes.

This primary education scheme has also shown a high Gross Enrollment Ratio of 93-95% for the last three years in some states. Significant improvement in staffing and enrollment of girls has also been made as a part of this scheme. The current scheme for universalization of Education for All is the Sarva Shiksha Abhiyan which is one of the largest education initiatives in the world. Enrollment has been enhanced, but the levels of quality remain low.

Private education:

According to current estimates, 80% of all schools are government schools making the government the major provider of education. However, because of poor quality of public education, 27% of Indian children are privately educated. According to some research, private schools often provide superior results at a fraction of the unit cost of government schools. However, others have suggested that private schools fail to provide education to the poorest families, a selective being only a fifth of the schools and have in the past ignored Court orders for their regulation. In their favour, it has been pointed out that private schools cover the entire curriculum and offer extra-curricular activities such as science fairs, general knowledge, sports, music and drama. The pupil teacher ratios are much better in private schools (1:31 to 1:37 for government schools and more teachers in private schools are female. There is some disagreement over which system has better educated teachers. According to the latest DISE survey, the percentage of untrained teachers (para techers) is 54.91% in private, compared to 44.88% in government schools and only 2.32% teachers in unaided schools receive in service training compared to 43.44% for government schools. The competition in the school market is intense, yet most schools make profit. Even the poorest often go to private schools despite the fact that government schools are free. A study found that 65% of schoolchildren in Hyderabad's slums attend private schools.

Private schools are often operating illegally. A 2001 study found that it takes 14 different licenses from four different authorities to open a private school in New Delhi and could take years if done legally. However, operation of unrecognized schools has been made illegal under the Right of Children to Free and Compulsory Education Act which has also significantly simplified the process of obtaining recognition.

Home schooling:

Home schooling is legal in India, though it is the less explored option. The Indian Government's stance on the issue is that parents are free to teach their children at home, if they wish to and have the means. HRD Minister has stated that despite the RTE Act of 2009, if someone decides not to send his/her children to school, the government would not interfere.

Secondary education:

The National Policy on Education (NPE), 1986, has provided for environment awareness, science and technology education, and introduction of traditional elements such as Yoga into the Indian secondary school system. Secondary education covers children 14-18 which covers 88.5 million children according to the Census, 2001. However, enrolment figures show that only 31 million of these children were attending schools in 2001-02, which means that two-third of the population remained out of school. A significant feature of India's secondary school system is the emphasis on inclusion of the disadvantaged sections of the society. Professionals from established institutes are often called to support in vocational training. Another feature of India's secondary school system is its emphasis on profession based vocational training to help students attain skills for finding a vocation of his/her choosing. A significant new feature has been the extension of SSA to secondary education in the form of the Madhyamik Shiksha Abhiya. A special Integrated Education for Disabled Children (IEDC) programme was started in 1974 with a focus on primary education. but which was converted into Inclusive Education at Secondary Stage Another notable special programme, the Kendriya Vidyalaya project, was started for the employees of the central government of India, who are distributed throughout the country. The government started the Kendriya Vidyalaya project in 1965 to provide uniform education in institutions following the same syllabus at the same pace regardless of the location to which the employee's family has been transferred. A multilingual web portal on Primary Education is available with rich multimedia content for children and forums to discuss on the Educational issues.
Higher education:

India's higher education system is the third largest in the world, after China and the United States. The main governing body at the tertiary level is the University Grants Commission (India), which enforces its standards, advises the government, and helps coordinate between the centre and the state. Accreditation for higher learning is overseen by 12 autonomous institutions established by the University Grants Commission.

As of 2009, India has 20 central universities, 215 state universities, 100 deemed universities, 5 institutions established and functioning under the State Act, and 13 institutes which are of national importance. Other institutions include 16000 colleges, including 1800 exclusive women's colleges, functioning under these universities and institutions. The emphasis in the tertiary level of education lies on science and technology. Indian educational institutions by 2004 consisted of a large number of technology institutes. Distance learning is also a feature of the Indian higher education system.

Some institutions of India, such as the Indian Institutes of Technology (IITs), have been globally acclaimed for their standard of undergraduate education in engineering. The IITs enroll about 8000 students annually and the alumni have contributed to both the growth of the private sector and the public sectors of India. However IITs barely has any contribution in fundamental scientific research and innovation. Some Institute of Basic research like Indian Association for the Cultivation of Science(IACS), Indian Institute of Science IISC), Tata Institute of Fundamental Research (TFIR) has acclaimed for their standard of research in basic science. Three Indian universities were listed in the Times Higher Education list of the world's top 200 universities - Indian Institutes of Technology, Indian Institutes of Management, and Jawaharlal Nehru University in 2005 and 2006. Six Indian Institutes of Technology and the Birla Institute of Technology and Science - Pilani were listed among the top 20 science and technology schools in Asia by *Asiaweek*. The Indian School of Business situated in Hyderabad was ranked number 12 in global MBA rankings by the Financial Times of London in 2010 while the All India Institute of Medical Sciences has been recognized as a global leader in medical research and treatment.

Technical education:

India's National Policy on Education (NPE) provisioned for an apex body for regulation and development of higher technical education, which came into being as the All India Council for Technical Education (AICTE) in 1987 through an act of the Indian parliament. At the Central (federal) level, the Indian Institutes of Technology and the Indian Institutes of Information Technology are deemed of national importance.

The Indian Institutes of Management are among the nation's premier education facilities. Several Regional Engineering Colleges (REC) have been converted into National Institutes of Technology. The UGC has inter-university centres at a number of locations throughout India to promote common research, e.g. the Nuclear Science Centre at the Jawaharlal Nehru University, New Delhi.

In addition to above institutes, efforts towards the enhancement of technical education are supplemented by a number of recognized Professional Engineering Societies like:

1. The Institution of Engineers (India);
2. The Institution of Chemical Engineering (India);
3. The Institution of Electronics and Tele-Communication Engineers (India);
4. The Indian Institute of Metals;
5. The Institution of Industrial Engineers (India);
6. The Institute of Town Planners (India)
7. He Indian Institute of Architects etc.,

Who conduct Engineering/Technical Examinations at different levels (Degree and diploma) for working professionals desirous of improving their technical qualifications.

Women's education:

The education of women in India plays a significant role in improving living standards in the country. A higher women literacy rate improves the quality of life both at home and outside of home, by encouraging and promoting education of children, especially female children, and in reducing the infant mortality rate. Several studies have shown that a lower level of women literacy rates results in higher levels of fertility and infant mortality, poorer nutrition, lower earning potential and the lack of an ability to make decisions within a household. Women's lower educational levels is also shown to adversely affect the health and living conditions of children. A survey that was conducted in India showed results which support the fact that infant mortality rate was inversely related to female literacy rate and educational level. The survey also suggests a correlation between education and economic growth.

In India, it was found that there is a large disparity between female literacy rates in different states. For example, while Kerala actually has a female literacy rate of about 86 percent, Bihar and Uttar Pradesh have female literacy rates around 55-60 percent. These values are further correlated with health levels of the Indians, where it was found that Kerala was the state with the lowest infant mortality rate while Bihar and Uttar Pradesh are the states with the lowest life expectancies in India. Furthermore, the disparity of female literacy rates across rural and urban areas is also significant in India. Out of the 24 states in India, 6 of them have female literacy rates of below 60 percent. The rural state Rajasthan has a female literacy rate of less than 12 percent.

According to a 1998 report by U.S. Department of Commerce, the chief barrier to female education in India are inadequate school facilities (such as sanitary facilities), shortage of female teachers and gender bias in curriculum (majority of the female characters being depicted as weak and helpless). Conservative cultural attitudes, especially among Muslims, prevents some girls from attending school.

The number of literate women among the female population of India was between 2-6% from the British Raj onwards to the formation of the Republic of India in 1947. Concerted efforts led to improvement from 15.3% in 1961 to 28.5% in 1981. By 2001 literacy for women had exceeded 50% of the overall female population, though these statistics were still very low compared to world standards and even male literacy within India. Recently the Indian government has launched Saakshar Bharat Mission for Female Literacy. This mission aims to bring down female illiteracy by half of its present level.

Literacy:

According to the Census of 2011, "every person above the age of 7 years who can read and write in any language is said to be literate". According to this criterion, the 2011 survey holds the National Literacy Rate to be around 74%. Government statistics of 2001 also hold that the rate of increase in literacy is more in rural areas than in urban areas. Female literacy was at a national average of 65% whereas the male literacy was 82%. Within the Indian states, Kerala has shown the highest literacy rates of 93% whereas Bihar averaged 63.8% literacy. The 2001 statistics also indicated that the total number of 'absolute non-literates' in the country was 304 million.

Attainment:

World Bank statistics found that fewer than 40 percent of adolescents in India attend secondary schools. The Economist reports that half of 10-year-old rural children could not read at a basic level, over 60% were unable to do division, and half dropped out by the age 14. An optimistic estimate is that only one in five job-seekers in India has ever had any sort of vocational training.

Higher education: As per Report of the Higher education in India, Issues Related to Expansion, Inclusiveness, Quality and Finance, the access to higher education measured in term of gross enrolment ratio increased from 0.7% in 1950/51 to 1.4% in 1960-61. By 2006/7 the GER increased to about 11 percent. By 2012, (the end of 11th plan objective) is to increase it to 15%.

The foundation needs to be very strong which will enable the children to have their set Goal and a clear Vision.

MESSAGE

Mrs. Geetha Nagpal
Vice - Chairperson
Krupanidhi Education Trust, Bangalore

I deem it a pleasure to greet the students, parents, faculty and other stakeholders of Krupanidhi College of Pharmacy, Bengaluru on the auspicious occasion of the Graduation Day. This is indeed a major landmark on our way to perpetuate excellence as a habit in this iconic campus.

Educational campuses have long life span so as to nurture generation of learners. These offer phenomenal spaces both physical and emotional for the students to create comfort zones of learning. The culture of a campus defines the future professional competence and career success of the students. Krupanidhi Group of Institutions is consciously aware of these influences for the future of our students. With this background, we have not only created a learning culture on our campus, but have also facilitated the architectural and intellectual harmony by providing an Arcadian haven for academic accomplishments. Our campus environs are designed to promote intelligent and personalised learning. It is a platform that facilitates the faculty and students to collaborate in academic spirit to nurture talent with enthusiasm, and thereby accelerating learning progress. The hallowed campus environs stimulate the learners' intellectual, emotional and social quotients for cognitive capacities, skill development and developing a sense of global citizenship.

Here teaching and learning are not the drab rigours of anaemic bibliophobia, but a lively and dynamic interaction for knowledge sharing and attitude shaping. In this quest, I must credit all our teachers who are open to break from the routine and weave a rich tapestry of innovative learning platforms. Our College of Pharmacy, the pioneer institute that founded the Krupanidhi culture has been a torchbearer. The faculty and students have always stood for the principles and philosophy that we espouse. It gives me a greater satisfaction to address the stakeholders of Pharmacy College through this commemorative volume.

I hope that the gains that we have made in the past, especially the human relations that we have developed in our alumni network will be the investments for future. We have huge trust in the warmth and faith that we have cultivated among our present and past students. This is the highest tribute that any human being can offer to another human being. I take this opportunity to greet and commend all the students, parents, faculty and administrative staff for this aura of optimism and euphoria. I wish you all the best.

MESSAGE

Prof. Sunil Dhamanigi
Secretary
Krupanidhi Education Trust, Bangalore

Training of Teachers: As the cliche goes, you cannot teach a person swimming by lecturing him on the topic. Then why do we persist in trying to train teachers essentially through theory classes and lectures? Isn't it ironic that trainee teachers have to sit through lectures which explain and exhort how learning by doing is the best way to learn? The result of an excessive theoretical training is that when they become teachers, these students know of no other teaching method themselves. They themselves use methods that kill innovation, make lessons dull and boring and evoke in children fear and hatred of learning. Pharmacy and teaching are two professions where theory and practice have to go hand-in-hand, day-to-day. Teacher training programmes today are heavy in theory and provide little provision for their trainees to practice. Can such training develop teachers who can excite and challenge children? Who will teach English, Pharmaceutics or Pharmacology, but first teach children? Who love their pupil, love teaching, know their subjects and have the requisite teaching skills? That is the kind of Teachers of tomorrow programme aims to develop.

Practical training should be supported by classes which include a variety of instructional methods like case studies, excursions, projects, seminars and meetings with practicing education professionals. The curriculum should be modern one designed on internationally accepted lines after studying leading teacher education programmes in India and abroad. Students are exposed to computers and the Internet from day one. Apart from this, one hour everyday should be set aside for activities like Personality Development, Yoga, Art, and Music/Dance. Finally, attitudinal training is a key component of the programme. After all, enthusiasm can move mountains, and more can be achieved by a group of positive-minded, enthusiastic teachers than merely capable ones.

Since the needs of the primary students are different from the secondary students, the primary teachers and secondary teachers are required to take up different teacher's training courses.

Need for National Mission on Education

1. Effective utilization of intellectual resources, minimizing wastage of time in scouting for opportunities or desired items of knowledge appropriate to the requirement,

2. Certification of attainments of any kind at any level acquired through formal or non-formal means in conventional or non-conventional fields,

3. Any-time availability of desired knowledge at appropriate levels of comprehension to all for self-paced learning.

4. Platform for sharing of ideas and techniques and pooling of knowledge resources.

5. Systematically building a huge database of the capabilities of every individual human resource over a period of time.

6. Scholarship / Talent management including identification, nurturing and disbursement electronically.

7. Nurturing of scholars and learners.

8. Capability to handle the user base

9. Use e-learning as an effort multiplier for providing access, quality and equality inthe sphere of providing education to every learner in the country.

10. Provide for Connectivity & access devices, content generation, personalization & mentoring, testing & certification and encouragement of talent.

11. Bringing efforts of different interested agencies working in the field of e-learningunder one umbrella and establishing logical linkages between various activities.

12. Capacity building in this sphere and utilizing dormant capacities of various organizations. Creating infra structural facilities for long term utilization and making sustained efforts for content generation & connectivity including access devices production.

13. Encouraging research in spheres covered by Mission activities.

14. Providing e-books & e-journals, utilizing the repository of contents generated so far and the automation of evaluation processes. Creation of a high impact brand fore-Journals in leading disciplines with a provision for good incentive-basedpayment to the researchers.

15. Spreading Digital Literacy for teacher empowerment and encouraging teachers to be available on the net to guide the learners.

16. Multi-lingual content development for the learners more comfortable in those languages.

17. Voice support for educational material delivery and interactivity for the content on the portal.

18. Development of interfaces for other cognitive faculties which would also help physically challenged learners. These efforts may cut across all the content generation activities.

19. Improving teachers' training and course curriculum.

20. Providing Digital/Information Literacy for teacher empowerment.

Nice quote by Max Leon Forman, "Teachers are people who start things they never see Finished and for which they never get thanks until it is too late".

MESSAGE

Dr. Samuel Paul Isaac
Campus Director
Krupanidhi Group of Institutions, Bangalore

It is indeed a pleasure and privilege to reach out to the extensive family of Krupanidhi Institutions through this pharmacy college souvenir. As the Campus Director, it is also an honour that I connect with my professional colleagues and the future professionals.

Krupanidhi has a tradition that symbolises honesty and accomplishment. As a representative of this great institution, I am humbled by the success that I see around me in the campus; the curricular achievements of students and faculty, the co-curricular triumphs of our students, the professional attainments of our faculty – all these lead to a narrative that stirs hope and anchors promise. The trends clearly indicate high tides of progress in the ocean of competitive excellence.

Our institute of pharmacy, which is the cradle of this group of institutions, stands out as a shining example of success personified. With the major upheavals in the domain of higher education and globalization of professional education, pharmacy education also must expect major influences to impact and draw the best from its professionals. The challenges faced by pharmacy profession are multidimensional. They range from the community expectations for rational drug practices to research and development of new molecules with ethical moorings.

The profession of pharmacy is at a significant crossroads between its conventional drug-dispensing identity and a pioneering clinical role with health care provider status. The perceived roles of pharmacist have made a paradigm shift from being a drug dispenser and compounder to someone who is a proud and responsible member of healthcare team. The healthcare delivery has

changed from unitary decisions made by the 'doctor' to a collective and collaborative teamwork, which has pharmacists playing pivotal role in decision-making for prescription, patient monitoring, corrective action in case of adverse drug reactions, among other responsibilities.

These challenges are consequent to the complexity of healthcare models, which lay premium on team-based approach rather than individualistic doctor-based model. As the intensity for patient care escalates, it further increases demands on pharmacists. It also provides opportunities for knowledge development and specialisation in pharmacy practice.

The common factor in all this is change: in education and training, in clinical practice, in work processes, in professional scope and expertise, in regulatory standards. Embracing change is essential to managing it. Infrastructure and resources are necessary enablers to implementing change, and measurement and reporting are important tools for communicating the impact of change.

I believe that over the next few years pharmacists will not only dispense medications but will also provide patient-centered, individualized pharmaceutical services. As tech-check-tech, the practice of one technician checking the accuracy of another, becomes more prevalent, the pharmacist will be available to practice more clinically. With more available time, pharmacists will have to prove their value within the setting, and provider status will allow for payment to occur. Furthermore, I believe that with provider status, pharmacists will need to have specialised training to work in these particular settings. Hopefully, with this new community practice setting, pharmacists will help to decrease health care costs and improve patient safety.

In this context, the expectations of society on the education providers are huge and humbling. The accountability for us is daunting and testing. Only the fittest and fastest will survive. I shall also add that only the committed and passionate will survive. This is indeed the core strength of our great institution. A visionary leadership, proactive management team, committed faculty, passionate students, appropriate facilities and above all the warmth and support in the environment have made our institutions hallowed temples of learning.

With this, I have the privilege of greeting my peers in the campus for a memorable graduation day, a remarkable event that will leave indelible impressions of joy soaked with contentment, a significant milestone in the journey that is also the pointer for the future directions in the path of success.

I am sure that the celebratory events will make this commemorative volume of scholarly write-ups blend the scholastics with enjoyment. This souvenir has many articles of interest that shall be preserved as references for the future learning and re-learning.

I salute all those who have made this event memorable and enjoyable.

MESSAGE

Dr. MD Karvekar
Director, Academics
Krupanidhi College of Pharmacy, Bangalore

Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis of Knowledge and Skill

A) Weaknesses Identified: Our ambition of India becoming a knowledge super powerby effectively utilizing abundant human resource faces the following weaknesses:

1. Abundance of un-nurtured talent.
2. Lack of timely and easy availability of knowledge resources to all.
3. Opportunities lost because of difficult access to information and guidance.
4. Mismatch between demand and supply of knowledge and skills
5. Lack of collaborative learning
6. Questionable quality of teaching at various places
7. Non-standardized testing
8. The lack of a legal framework that links the qualification and certification frame work to the prescribed requirements for the job and a regular performance appraisal of those who prepare the content and of those who deliver and teach it.
9. The growing digital divide
10. A lack of personalized monitoring and long term tracking of growth and enhancement in learning, skill and performance.

11. A very low percentage of digital literacy

12. Lack of encouragement to excel

13. Substantial duplication of efforts at various levels

14. Time mismatch between school hours and employment hours for those learners who have to simultaneously earn the livelihood for their families.

15. A lack of access to institutions

16. A lack of access devices to digitally bypass shortcomings of Institutions and teachers

17. A lack of multi-layered networks for knowledge absorption and knowledge propagation.

18. The lack of a strong contingent of motivated teachers.

19. Inefficient functioning of the knowledge delivery mechanism.

B) Inherent Strengths: On the other hand, we have the following inherent strengths:

1. A large human resources of high intellectual caliber

2. A large number of expert faculty in almost every field

3. A growing middle class with a high priority for education

4. A number of world class institutions of learning & research

5. Technological and Communication backbone to take their advantage in the field of knowledge empowerment of the mass of learners.

C) Opportunities on the horizon:

1. Falling cost of hardware

2. Falling cost of bandwidth

3. A high growth in mobile density

4. Availability of Edu SAT

5. Availability of proper infrastructure

6. Rapidly expanding Optical Fibre Cable network for terrestrial broad and connectivity.

7. The advent of very low power consumption connectivity & computing devices

8. The abundance of knowledge on the internet

9. Rapidly expanding network

10. Knowledge enhancement at any age, any place, any time, any direction.

D) Threats looming large:

1. A growing knowledge divide may soon endanger the fabric of social harmony

2. Other countries, managing their educational infrastructure well, may provide initialed to their children which might get multiplied as the time progresses

3. If delayed, other countries may wrest the IT based initiatives from us.

With an ever expanding field of knowledge, the knowledge and skill sets required by an individual to successfully lead life has also expanded, throwing up challenges of learning more and more throughout one's life. Add to that challenges of pedagogy being faced by the teachers to package more and more for the uptake by the students within the same amount of time available.

Inspection:

The most powerful forms of education are meaningful, involve the student, promote critical thinking, and appeal to different learning styles. The mission is to provide educational experiences in the classroom, assisting educators with curriculum needs and offering activities that enable students to investigate, research, and participate in interactive learning. Inspection is concerned, in the main, with the improvement of standards and quality of education and should be an integral part of a college improvement program. The rational for this improvement is three folds (a) the universal recognition of the right of every child in every classroom, in every college to receive a high quality education appropriate to their needs and aptitudes; (b) the effectiveness in education system is a key influence on economic well-being of every nation; and (c) the recognition of the need to equip students with the kind of education that will enable them to contribute to increasingly complex and changing society. In many countries where inspectoral system of supervision of colleges is conducted, the responsibility for college inspection lies with the Inspectorates.

Inspection, as a mode of monitoring education, offers the following major benefits

- It gives inspectors an opportunity to observe classrooms and, thereby, a better basis for discussing the development of the College.

- It gives college inspectors an opportunity to learn about the colleges, the Principal, the teachers, the curriculum, and the students and indicates which way forward;

"Facts do not cease to exist because they are ignored." -Aldous Huxley

- It can be a potential learning experience for those involved;
- It should provide useful information for parents in their choice of colleges;
- It leads to a better understanding of colleges;
- It enhances staff cooperation and public recognition that the college
- It boosts staff morale;

Strengths of the Proposed Inspection Framework

The proposed inspection framework has the following potential benefits:

- It is likely to make the current inspection system more effective than ever before. "an effective inspection system can provide a powerful incentive for, as well as directly contributing to college improvement and development"

- The results of inspection process under this framework should meet the concerns of the different stakeholders as follows: (a) accountability to pupils, to parents, and to tax payers, for the college's promotion and pupils' achievements, as well as the value for money invested in education;

(b) consumer choice of colleges through the publication of appropriate inspection reports, including summaries for parents to choose colleges; and (c)college, improvement through the use of inspection reports by colleges and their governors as both an educational audit and as a tool to help refocus priorities and targets for improvement; and

- The framework should form a fair and cost-effective basis for inspection of all colleges.

MESSAGE

Prof. Prakash V Mallya
Director, Centre for Pharmaceutical Professional Advancement
Krupanidhi College of Pharmacy, Bangalore

Pharmacy-The most Trusted and Respected Profession, A Prescription for a Richly Rewarding Vocation

Pharmacy is a noble profession being practiced since ancient ages. The Pharmacy profession has grown manifold and the role of pharmacist in current times is indispensible in healthcare ecosystem. The multi-dimensional growth in Pharmaceutical Sciences and Pharmacy Practice has increased the scope of the Pharmacy professionals to a great extent. For many years pharmacy has been ranked as one of the most highly trusted professions and has been recognized as one of the TOP health care career by Forbes and other Gallup survey.

Pharmacy is and always has been a rewarding profession that provides valuable services and unmatched access to healthcare. In The ever expanding vocation, the pharmacists manufacturer medicines, keep Quality control and Develop new drugs through Research and development. Further with improvement in healthcare and increased purchasing power in the growing economy people are spending a lot of money on wellness and fitness products along with prescription and OTC drugs. With increase in life expectancy, elderly population is also growing and hence their medical care and increased need of medicines.

The pharma industry is experiencing a paradigm shift with exponential advancements. Multiple range of systems are available to support the work flow and harness the technology for the pharma Industry's growth. These emerging technologies will play an important role with respect to identifying precision targeted and cost-effective therapy or using social media to get Doctors connected with the Patients. Concurrently Extraordinary new

developments in enabling technologies - from miniaturized drug diagnosis and delivery systems to powerful visualization tools and measurement techniques - are reshaping the markets, strategies and futures of pharmaceutical and biotechnology companies around the world.

Having said that, the role of pharmacy graduates will continue to develop and expand, in the fore seeable future regardless of your chosen area of specialization. As you embark upon and progress through your careers, all of you have the opportunity to enrich the lives of those around you. I urge you to always remember why you chose your respective field and the sacrifices that you endured in order to make it happen: to serve our communities and improve the quality of life and health of the humanity with compassion, honesty and integrity.

I consider myself blessed to have spent 4-plus decades in this field. Therefore have no hesitation in giving you a few suggestions. First, Be optimistic, and have faith that you have chosen the right profession. It is a profession that will serve you well. By that I mean, fully dedicate yourself to making the most of your pharmacy education, and prepare yourself for the future in ways that maximize your self-worth and your full potential.

Study diligently for the sake of expanding your skills and knowledge, not just to pass exams. When engaged in a real-life training experience, treat it as a 24/7 learning, development and quality of life enhancing vocation. Impress everyone at the training site with your work ethic, your commitment to excellence, your service-oriented mentality, your compassion for all people, your emotional maturity, and your ability to work well with others. In short, put your best foot forward at all times. People tend to notice a positive attitude, a willingness to work hard, and a trustworthy character. If they witness such attributes in you, they will want you to be a member of their team.

Also, get involved in supporting, promoting, and developing your profession. Be an advocate for pharmacy issues, and prepare yourself to be a pioneer of progressive new roles and services. Become the kind of pharmacist who feels compelled to blaze a trail where one does not already exist. "we tend to reap what we sow" ,is a well-worn biblical expression. Students who sow a great education are destined to reap the rewards of a great career. If you follow this advice, grounded in a sense of humble gratitude for the talents and opportunities that have been afforded to you, The Industry, Hospitals and employers will eagerly seek to hire you.

The Profession of Pharmacy can be summarized thus;
A vital part of the health care system. Pharmacists play a vital role in improving patient care through the medicine and information they provided A trusted profession. Pharmacists are consistently ranked as one of the most highly trusted professionals because of the care and service they provide, according to perceptions of honesty and ethical standards. *According to data by Gallup International A well-rounded career. Pharmacy is an exciting blend of science, health care, direct patient contact, computer technology, and business Outstanding opportunities. There is an unprecedented demand for pharmacists in a wide variety of occupational setting. Excellent earning potential. Pharmacy is one of the most financially rewarding careers.

A whole science of emerging opportunities will arise in fore seeable future viz; Nuclear Pharmacy. Nutrition Support Pharmacy, Oncology Pharmacy, Psychiatric Pharmacy, Forensic Pharmacy, Space Pharmacy etc be well prepared for the rapid changes, the scope is immense.

Best wishes for an Excellence in Academics and a Brilliant Career

MESSAGE

Dr. Raman Dang
Principal
Krupanidhi College of Pharmacy, Bangalore

We are NAAC Accredited. The highest body in the country has put its well-deserved seal on one of the most reputed institute in the country.

Krupanidhi College of Pharmacy is always the prime runner for quality. Our focus is to touch the top levels of research but remain grounded to the basic core levels of education.

The new academic session is preferred to state from 1st August as per Supreme Court directive to all pharmacy institutions. We commenced with orientation and induction of the new batch. A grooming session is followed where the students and parents were made aware of the intricate parameters of education and importance of the industry/clinical segment in a very interesting way.

The lacuna is in correct communication. The knowledge base and adaptability is high among today's students.

The entire calendar of events was diligently followed with complete effective execution.

Each festival and occasions of importance to pharmacists were celebrated in a big way. Many Luminaries in the pharma field addressed our staff and students. There was conduct of regulatory certificate course for the outgoing students. The entire process was spearheaded by Prof. Prakash Mallya, Director CPPA.

The routine seminars, workshops on every Saturday were at its best. The top speakers from all pharma field were invited. The sessions were made very interactive. Finishing school which is an exclusive feature at Krupanidhi was

conducted to train the students to face the interviews handle critical issues, to effectively convey and present.

Campus interviews saw many top industries and hospitals coming at our institute. The placement team left no stone unturned to cater to the interest of students. The on and off campus interviews and drives saw 100% placement for all the interested lot.

Compulsory training to Industry and internship in Hospitals was meticulously organized and each student was given personal attention and care to get his choice. The merit and overall performance of the students played the key role.

Excursions, field trips, Industrial & hospital visits are here to stay students enjoy every bit of this teaching learning process.

Staff and students participated and presented their work at national and International level.

Many new collaboration came in with the Industries and hospitals of concern.

We won top positions in many of the cultural National / State events. The moment of pride was to secure 100% results in many of pharmacy specializations. Top ranks were bagged by our bright students at the university level. The first and second rank in Pharm D (PB) was few among our glory story.

University Journals and the In-house international Journal both of which has high readership base among the scientists and researchers worldwide are published from Krupanidhi college of Pharmacy.

Dr. Raman Dang, the principal who has taken over as BOS chairman PG for the affiliating university contributed immensely to raise the standards of research and the smooth conduct of examinations. The JT secretary of APTI organized a historic collaborative education methodology workshop with the university. Each activity at the institution, university, state, National and International level were lead from the front. It was seen that what was committed is delivered to perfection.

Dr. Sonal Dubey, the silent worker brought in Rs. 12 lakhs of research grant to the institution for "Drug Design" Dr. Kuntal Das is working totally towards the upliftment of research and got is Rs. 1.5 lakhs of Grant to work on cell lines.

Green Chem our collaborative industry partner has constituted Rs. 1 lakh of Grant for academic excellence. Which is given to toppers in every field and specialization of Pharmacy. Krupanidhi Management took initiative to give 100% Scholarship to deserving economically backward students.

NSS unit headed by Mrs. Rajeswari R the epitome of perfection conducted the NSS camp and various other programs for the society. *Synegia* the Pharm D news letter under her editorship has seen new light and is circulated well.

"The Journal of Pharmaceutical Research, the in house pride now has Dr. Sonal Dubey and Mr. Chandramouli R at the helm of affairs. It is the dream of our Chairman Prof Suresh Nagpal and brainchild of Dr. R S Thakur. The Internal Quality Assurance cell is doing well and documenting each and every episode happening at Krupanidhi College of Pharmacy. There was signing of may international MoUs at the campus front. The entire working system is being effectively upgraded to give the best result and facilities to the students.

The staff and students are involved in short term research projects, National Conference and various other events of institution branding shaped up well.

The drug information centre and Pharmacovigilance cell at one collaborative hospital at MVJ is doing exceptionally well. Krupanidhi always has a vibrant atmosphere. The personnel here are very innovative and contribute to the core.

Concluding Note: United we stand tall and work for our institute and the profession of pharmacy as a whole.

God Bless, Keep Shining

2016

EXPRESSIONS

Team KCP

KCP Faculty


"HAPPINESS IS NOT SOMETHING READYMADE IT COMES FROM YOUR
"EDUCATION IS THE MOST POWERFUL WEAPON WHICH YOU CAN USE TO
10 Amazing Life Lessons
" WE SHOULD NOT GIVE UP AND WE SHOULD NOT ALLOW THE
LIFE QUOTES
Arise ! Awake ! and stop not till the GOAL is reached

KCP Non Teaching Staff

Editorial Team of *Expressions 2016*

Journal of Pharmaceutical Research - Core Team

Journal of Pharmaceutical Research - Editorial Team

2016

EXPRESSIONS

Life@KCP

Life@KCP





IPC







IPC



SnS

DESIGNS

We make ladies & Gentlemen

BLAZERS SUITS TUXEDOS BANDHGALA SUITS

CORPORATE SUITS CORPORATE UNIFORMS

COLLEGE UNIFORMS

snsdesignsbangalore@gmail.com

+971 988 618 3323 / +971 9060 12 4041

Our Partners

Desi diva

Agni

2016

EXPRESSIONS

Confab

- 6 time National Award Winner
- 2 time FKCCI Gold Award Winner for Best Export Excellence 2012 & 2015
- FKCCI Innovation Excellence Award 2014 & 2015
- VTPC Export Award 2013-2014
- Chemexcil Export Award 2010-2011
- 46+ Global Patents
- USDA & EU certified organic products
- AYUSH Partner
- ISO 22000 : 2005 certified

"Assuring quality from the root upwards"

At Green Chem, we have fine-tuned the medicinal healing therapies of ancient India. We have been in the nutraceutical business for over a decade with three decades of experience behind us.

We owe our global success to our in depth knowledge of the active ingredients derived from medicinal plants coupled with our commitment to quality.

Our proven capability to research, manufacture and market high value herbal ingredients is an endorsement of our ability to meet global benchmarks.

HERBAL INGREDIENTS FOR

- Anti Obesity
- Anti Diabetic
- Libido boosters
- Anti Cholesterol
- Energy boosting
- Anti Arthritic
- Anti Stress
- Bone strengthening
- Memory enhancing
- Anti Cancer
- Laxative
- Skin conditions
- Capillary protecting
- Immuno modulating
- Natural Vitamins
- Natural Minerals
- Cardiac Health

OFFICE

"Lakshmi", 5 BDA, 2nd Stage,
3rd Phase, Domlur,
Banglore–560071, India.

Ph: 080-2535 9569
www.greenchem.biz
info@greenchem.biz

Green Chem®

HERBAL EXTRACTS & FORMULATIONS

EXPORT

100% Export Oriented Unit

We are a 100% Export Oriented Unit and have been serving global clients for over a decade.

CERTIFICATES

ISO 22000:2005 Certification

We have been awarded ISO 22000:2005 certification. We have introduced many certified organic extracts in the U.S., Germany, France, etc., We are also Kosher and Halal certified.

QUALITY CONTROL

Assuring pharmaceutical quality

Our specifications include physical, botanical & chemical parameters, quantification of active compounds, complete microbial profile, heavy metals profile, aflatoxins & organoleptic parameters.

MANUFACTURING

1500 tons Annual Extraction Capacity

We manufacture herbal extracts as per cGMP, in a state of the art facility located in Bangalore, India.
Our annual Extraction capacity is 1500 tons.

R&D

In house research & development

We carry out in house research and development, animal studies, clinical trials, toxicity studies and safety studies.



CULTIVATION

Traceabilty through backward integration

We ensure traceability and enforce quality through backward integration. We cultivate herbs in our own organic farms.

"My vision led me here"

Ramaswamy Rajendran (RR) is the Founder & CEO of Green Chem and Natsyn Catalysts, two natural product firms that innovate herbal formulations and supply bulk natural product ingredients with Pharma Quality, across the world.

He learned to love and respect nature at an early age from his grandfather, this triggered his lifelong passion for medicinal plants. Following an MSc in Biochemistry, he worked with several prestigious companies and has served as President and Chief Operating Officer at Sami Chemicals, Technical Manager at Cipla and Research Scientist at Kothari Phytochemicals. In 1997, after several years of acquired knowledge and expertise, he decided to pursue his true calling by launching Green Chem along with his wife and business partner Kamala Rajendran (KR), and the rest is history. Today, R. Rajendran is a respected professional in the herbal, pharmaceutical and nutraceutical world, with over 42 years of leadership in the field.

Rajendran and Kamala have won recognition as innovators, have a number of patents to their name, received several national awards, published scientific papers, addressed seminars, and built a reputation for developing quality products, encouraging research into new formulations and maintaining sustainable productivity for the global market. Green Chem is presently

R Rajendran
Founder, CEO Green Chem (R)

helping the Indian Government establish herbal monographs for the Ayurvedic Pharmacopoeia of India. Rajendran also serves as an industry advisor for academic projects at Harvard Business School.

As we reached the venue – their well appointed offices in Domlur, Bangalore, we were quite anxious but at the same time excited to meet a person of such caliber. We were ushered to his office where Rajendran was seated with his wife Kamala Rajendran who greeted us warmly and made us feel at ease. After exchanging brief pleasantries we were joined in by their son Ravi Rajendran, who is a Harvard Bussiness School alumnus, carrying on his parents' legacy. The interview was a stimulating and an enriching experience for all of us. Rajendran, Kamala Rajendran and their son Ravi Rajendran spoke with such poise and humility which was truly inspiring. Here is an excerpt of the interview. Hope you enjoy it as much as we did.

Interviewers:
Riju Patak (RP), Trushit Patel (TP), Preeta Caroline (PC)

Tagline: My Vision led me here

RP: What ignited the spark in you to start this business venture?

RR: It is mainly the scope available.

During the starting days of my career, what I realized was that there was no innovation or newness in the market as everyone was working on the same thing one way or the other.

Furthermore, India has many herbs and herbal products available. The wealth of knowledge available is tremendous but we do not realize it and additionally one could also witness how people adulterate the product and play with the minds of the customers in the market.

So after seeing all these, we got some sort of ignition in our minds to produce quality oriented efficacious products. We considered extracting the contents from the herbs and studying their properties scientifically so that it is more constructive against adulteration which is only destructive. With such vision and scope we decided go into the market and take up the herbal sector in which India is very strong.

PC: What would you say are the top three skills needed to be a successful entrepreneur?

RR: First of all, you should have a clear VISION. Try to focus where you would want to be five years down the line and keep a target on that.

In my own case, I had set up a Vision in 1997 of producing quality herbal products for the consumers and started a

Quality Control(QC) Laboratory with my wife who is an expert in QC .We used to buy the ingredients from the market, test it for quality and then supply it to the formulators/consumers with a consistent quality. Later we identified the market demand particularly in USA and started manufacturing ingredients by ourselves, tested and supplied. Gradually we did the "line extension" by own cultivation, later specialised into certified organic cultivation. We achieved a massive growth because of the Vision we targeted.

Secondly, Second skill is that you need to be willing to take RISK but also be careful as it maybe money related as well. Every step requires time, you may succeed or fail , regardless of that, you need to put sincere efforts, take the risk and just do it.

Third skill is TIME MANAGEMENT. You need to work on micro planning and time plan everything to come up with the product and hit the market.

TP: Being first generation entrepreneur in an Indian set up is usually discouraged upon, so what triggered you, based on your family background, to enter into this field?

RR : My interest into herbal medicine was triggered very distinctly at an early age when I used to witness my grandfather and father using Neem or Tulsi or Aloe vera from our home garden to cure common ailments instead of using allopathic medicines.

With this interest, I joined Kothari Phytochemicals, in 1974 which was working in the herbal field. During my early career, I worked in the Pharmaceutical companies, from the learning here, I could relate how drugs regulate body functions.

This gave me a stronger push towards herbal products and after joining Cipla, which worked in both herbal and pharmaceutical medicines, I had a clear concept that herbal products too need to be treated as pharmaceutical products in terms of quality, safety and efficacy because pharmaceutical standards are safe for human consumption and this needs to be adapted into herbal products. This is exactly what we do in Green Chem : "Offer herbal products with Pharma Quality".

TP: What have been some of your hurdles, and what have you learned from them?

RR: The major hurdle is to develop an innovative product which is different from the existing ones.

Also there are hurdles related to inadequate government regulations. They need to put up restrictions for controlling spurious products in the market.

It is also difficult to find the right "need of the hour" product for the consumer. The formulators are confused on how to select the product out of the many in the market. We, hence, educate our customers on the product and they are satisfied to work with us. We get the focus when we analyse data on various ailments recorded internationally. For example, Cardiovascular disease is on the top ailment, followed by Obesity and so on. We targeted these two ailments for developing herbal alternates.

Supplying of materials within a short span of time is another difficult task. So we have to take the risk and make inventories in different countries. So when the customers want the product, they can walk in, take a sample, analyze it and if they like it, they take it on spot. This is how we make the work easy for both.

These are the hurdles we normally face or have faced and worked out all these strategies and the minds of the customers, in order to ease the scenario and do good business.

PC: How many hours do you work in a day on average? Do you get time for family and vacations?

RR: Even 24 hours in a day does not suffice when it comes to work. But since my whole family is involved in my business venture we spend a lot of time together. Often business trips and business expos abroad double up as vacation.

RP: What kind of support have you received from your family and how important has it been in your path to success?

RR: It is important to have family support along with your internal passion and hard work. The presence of the latter two without any motivational factor can be a problem and that is where you need your family to work as a team with similar wavelength.

I have been lucky that our family works as a team round the clock. My wife is a technical person and all the achievements made so far have been through our combined efforts. It is also amazing that both my sons have had interest in this same field right from their school days and it has, hence, been easy for me to work long hours in the laboratory since the entire family is working in the same direction.

PC : How did the idea of monetization of traditional herbal knowledge come to you and what steps did you take in that direction?

RR : It all started from the forests. We go to different places and identify the clues that come from the traditional knowledge of the tribal, and refer back into the books of Ayurveda to check if they are reported or not which helps to figure out their potential in delivering the expected action. After developing the product, the safety of the herb with respect to long term use has been proven, then we go for commercialization of the herb. We respect Biodiversity rules and hence we go for propagation of the herb by cultivation and tissue culture techniques. This satisfies our responsibility of giving back to Nature what we have taken! One such example is of our product SLIMALUMA, the base knowledge about which was obtained from the forests. It was then brought to the laboratories, cultivated and developed the extract scientifically and produced with pharmaceutical standards and finally is sold to the consumers. In addition to this the tribals are employed in cultivation and suitably shared the benefit!

TP: To what do you most attribute your success?
I attribute my success to mainly three things:

1. Commitment to quality
2. Delivering consistent quality
3. Innovative products

PC: Why hasn't your company launched any FMCG (fast moving consumer goods) product so far?

RR & KR: Our current mission is the preparation and marketing of herbal extracts of herbal extracts to the formulators, but a future product line extension of this mission is the formulation of consumer products. We are planning on bringing about an innovation in herbal formulations in the form baked foods like pizzas, cookies and also in beverages. By doing so we intend to remove the stigma attached to consuming medications as the formulations are more patient friendly.

TP: What do you think is the major difference between being an entrepreneur and working for someone else?

RR & KR: There is a difference. I being an employee earlier in my career know that as an employee in 99% of the cases the work becomes monotonous and innovation is almost nil. But as an entrepreneur your mind is never at rest as you will be continuously tackling situations, planning ahead and thinking of innovative ways to improve the company.

RP: Does the experience as an employee help when you become an entrepreneur?

RR, KR: Yes. Becoming an entrepreneur is a gradual exercise. No fresh graduate is equipped to become an entrepreneur unless the family has a business background or experience. For example my son Ravi already had a company run by us which he would eventually take over, nevertheless he worked at KPMG for a couple of years after his graduation from the Harvard Business School and this helped him bring in new ideas, systems and innovations to our company.

TP: You as an individual as well as your company have received a lot of recognitions and awards nationally as well as internationally. How do you feel about the success you have achieved so far?

I am quite happy but not yet contented as I still have a long way to go. So far we have been successful in delivering herbal extracts to formulators but I wish to venture into formulation of consumer products in the future.

PC: Where did your organizations' funding/capital come from and how did you go about getting it? How did you obtain investors for your venture?

When I was younger my father had advised me against taking loans, so that stuck with me. (Laughs) So I started out my business venture by using my Provident Fund earned by working at previous companies and also the savings, for which I have to thank my wife. I was offered loans but I was against it and hence avoided it. We started out small but gradually developed and now we have reached a level where I can offer loans to other people. (Laughs)

TP: In a single phrase, how would you characterize your professional life?

Exciting, good but still a long way to go.

PC: How do you build a successful customer base?

When it comes to building a successful customer base quality and innovation play the trump cards. If you have these two factors the customers will automatically come to you. In the case of my company, the product efficacy was justified and backed up with scientific data. There are broadly two kinds of consumers, the people with a scientific background, for example: a pharma background and people who are unaware of the product efficacy. We targeted the former group which helped us build a good customer base. In any field or industry innovation is the key to building a successful customer base.

RP: How do you find people to bring into your organization that truly care about the organization the way you do?

RR: It is a very tough job actually. When we interview a candidate, we look forward for a particular quality, which is, the willingness to learn. Even though an applicant does not have a deep knowledge on various aspects, but has the willingness to learn, he is the one for us.

TP: What future vision do you have for your company apart from having consumer products?

RR & KR: Second to having consumer products, we also plan on setting up a Research Center, hopefully in the next 4-5 years time.

Our main objective is to try and get the tribal knowledge on herbal medicines and also that from Ayurveda and prove the same scientifically. We will also perform studies on Safety & toxicity including teratogenicity and ensure that the herbal product is safe to use in the long run over the generations.

We believe that it is essential to treat any new herbal product in the market as a pharmaceutical product which should be tested and proven safe and efficacious. This is our mission for the future.

PC: What three pieces of advice would you give to the college students who aspire to become entrepreneurs in future?

RR: It is very simple.

First, you need to identify the area of your interest and ensure that it is your real interest and not just something superficial out of external influences.

Second, you need to set your interest as your target and work towards achieving it. You can either work in a company /institution working in the same line or start something on your own and implement it.

Third, during implementation, you need to be little innovative and think out of the box. If it clicks to you as something right, take the risk and work on it. You will definitely succeed.

One important piece of advice would be that sometimes, during implementation you might encounter failures as well, do not panic. You can review your interest based on your pathway and take the right deviation for the betterment and reach your ultimate interest and do something innovative to stand out in the crowd.

For example:

At the start of my career, my aim was to set up a biochemical laboratory, but somehow it was not possible. Instead of losing hope, I reviewed my interest and realized that I can set up a herbal chemical laboratory as well since I was working in the same line and then went on to set up my own company. My main interest all these while had been on testing Quality and finally I have managed to be in the Quality ambit.

Another example is my second son Krishna Rajendran. He is very keen on doing something different to what I am doing. That is Marketing. He is learning now marketing by Supply Chain Management for which he is doing his Masters in MIT (Massachusetts Institute of Technology), Boston!

I am sure he will bring in the line extension for our business to reach our consumers!



"A lots still need to be done"

Philipe Haydon is the CEO of Himalaya Healthcare, an iconic Indian Pharmaceutical major that operates in the traditional wellness segment.

Philipe Haydon has scripted the success of Himalaya Healthcare and has established Himalaya as a world leader in the herbal drug and cosmetics.

He is one of the rare breed of people who has started early in life with considerable odds and has changed his destiny and the organisation he is associated with. Starting at the lowest rung of Himalaya at 18, he leads it now to greater success. Philipe Haydon is also an accomplished singer and a rock guitarist and performs professionally when his time permits.

In an email interview to Expressions 2016, he answered diverse questions on pursuing career success, and life.

Unlikemany other top executives in the pharmaceutical field, you have scripted your success from an 18 year medical representative to a CEO. In your opinion, what are your three qualitiesthat took you to being what you are today?

I began working with Himalaya at an early age which has created an unshakable belief in its innate strength to be a truly Indian multinational.Over the years, I have learnt that success is all about tenacity and empathy.

Himalaya Healthcare over the last decade has diversified into FMCG business and is in direct competition with huge MNCs and has created a dent in their market share which was not possible by any other Indian player. How did you achieve that?

We targeted emerging categories like face washes with innovative products. That was a game changer for us. We played to our strengths of being a herbalbrand which stands for "well researched and scientifically validated products". Ourcustomer-led communication strategy has helped to generate trust. We have since entered other categories with products that represent the core essence of the brand. For example our Sparkling White Toothpaste has natural bleach as opposed to chemical bleach and our Strawberry Lip Balm uses natural colors. We will continue to create products that are rooted in 'natural goodness' and made in India.

Philipe Haydon
CEO, Himalaya Healthcare

You have created a new paradigm in pharmaceutical sales when you took over Himalaya and basically scripted a new play book for successful product promotion. How did you activate that in a small span of time?

Here are five things that made the activation possible:

1. I spent over two decades on the field and understood that doctors were getting busier and had lesser time for product details. We created strategic business units, expanded our field operations and met specialty doctors promoting select products that had relevance to their practice.

2. We increased our presence by a fourfold multiplication of our field staff to achieve extensive coverage of markets across the country.

3. We were pioneers to understand the importance of the growth of Indian rural markets. We created a special strategic business unit to address customers in these markets.

4. We have a team that reaches out to Allopathic Doctors in Medical Colleges with the objective of helping the wider medical fraternity to understand how Ayurveda can play a role in providing holistic treatment options.

5. We invested heavily in training teams to communicate the safety and benefits of using our products for longer periods of time without adverse effects.

Unlike allopathic products which has a huge user base, Ayurvedic products are more lifestyle products and has limited prescribers in comparison; yet Himalaya has become an iconic brand which is trusted by allopathic practitioners too, how has it been possible?

Allopathic products are designed to be a fast cure for acute conditions. Ayurvedic treatments on the other hand are more slow acting and are a better treatment option for health management and chronic conditions. Not only is it safe and effective, it also treats medical conditions holistically.

We promoted Ayurveda by rationalizing the science behind it, testing formulations rigorously at our R & D Center, and validating them through innumerous clinical tests inmodern Allopathic medical colleges and hospitals. We were able to win over the allopathic fraternity by demonstrating the research strength our products are based on.

The modern prescriber is looking for products that are safe, effective and validated by clinical trials in reputed institutions. We created powerful marketing strategies resembling those used by allopathic products to reach out and create awareness.

All these efforts have made our products stand the test of time while also addressing the unique needs of the modern prescriber. Today, Himalaya is prescribed by over 400, 000 doctors.

Himalaya is one of the trusted brands in international markets. Yet, we are not successful in showcasing our healing heritage like Traditional Chinese Medicine, what needs to be done to remedy that?

The Indian Ayurvedic industry has remained fragmented for a long time. Many elements worked against its favor - lack of strong regulations, limited research, absenceof quality guidelines and limited government patronage.

The industry has changed rapidly since. Government is increasingly promoting Indian traditional medicines under the aegis of AYUSH.

A lot still needs to be done. The Indian Government needs to continue promoting Indian Traditional Medicine (ITM) across the globe and regulate the market to keep product quality that matches international standards. A notification from the Indian Government providing clarity on the usage of ITM is necessary. This will motivate doctors in medical colleges and institutions to prescribe and dispense AYUSH medicines as both the first line of treatment for every day illnesses and to improve quality of life for chronically ill patients. This will also encourage private practitioners to recommend ITM in their practice.

All herbal products are available over the counter. Hence doctors from across disciplines and practices should be allowed to recommend them. Today, there is some confusion about cross practice. It is important for the Indian Government to dispel this confusion in order to boost Indian Traditional Medicine.

How much of Himalaya's revenue is invested back into R&D?

R & D projects get top priority in terms of our spends.

You are an accomplished Rock Guitarist and have played in a professional capacity until recently. How did you find time to pursue your passion? At any point in time have you ever thought of switching to a musical career?

I am asked this question often and my answer remains, especially if you are working - find a hobby and pursue it. It is only a matter of priorities, if you have the passion, you will find the time. I've been playing in the professional circuit since I was 17 and I still do.

My full time musical career ambition remains on the horizon. One day, when I have made Himalaya products available in each and every home in India, I will be a full time musician.

What advice would you give our student readers to succeed in their profession as well as their passion?

Since the younger generation loves lists, I will end this as a 6 things Haydon recommends to succeed in life list:

1. Do things that you are passionate about
2. Train hard and work harder
3. There is no substitute for honesty & sincerity.
4. Practice empathy
5. Dream big
6. Never give in, never give up!

Fostering Pharmaceutical Excellence


राष्ट्रीय सेवा योजना
NATIONAL SERVICE SCHEME
NSS@KCP

2016

EXPRESSIONS

Cognise

Ajit Kaikini
Director
Growth & Corporate Training, Buoyancee
www.buoyancee.com

Choose to Take Charge & Lead Change…
Choose to Lead Change!
To Perform Well & for Well-Being - Choose to Lead Change.

We want our cricketers to perform well, the film to be extraordinary, the driver of the bus or the pilot to perform and give a smooth ride… am I performing well in life?

Am I able to choose right and keep life excited doing the right things right?

Am I using my imagination and living a life that is making my life extraordinary?

Surprisingly, it is very easy to perform better. After all, I own my own life, my thinking, my feelings however, is it truly under my control or are we slaves to circumstances around?

Only those who Choose to Lead themselves & the Change, are those who live life well! They are ALIVE!

Take ownership of your life. Stop complaining & start contemplating how to lead change - step up the quality of your life! The Time, Energy, Attention & Resources (TEAR) required for complaining or contemplating are the same. One gives tears of sadness while the other gives tears of happiness - choose your tears.

Life is extraordinary for those who know how to lead change - don't miss the chance to understand the changing trends in life, and in business, to be vibrant and successful! Keep upgrading yourself, the way you want to upgrade your devices and life-style.

Choose to Lead Change to take life from Good to Great to Amazing!

And when you leave this Earth - you are sure to get a standing ovation by your people around, for the wonderful extraordinary performance given!

TIPS: Talents, Interest, Personality to be aligned for Success & Significance towards a Fulfilled life!

- What are your natural gifts that are uniquely yours - and no one else's? (Discover your Talents & Traits)
- Which areas of expertise you are exceptionally brilliant in - that very few can compete with you ever? (You will have high level of Interest in this)
- Finally, how to combine your unique talents, knowledge & gifts, to live wildly rich & successful for the rest of your life? (Hone your tools, skills & attitude for a powerful personality)
- For all other requirements to reach your goals, anchor to the TIP in your team.

You may not have all the needs to reach your goals however, create a respectful team around, and achieve your objectives with team symphony. Akbar the great did it centuries ago, why not you?

Understanding the process helps:

1. Know yourself better! Who you are, how you operate, and what are your aspirations, needs, wants, hopes for, and the direction of your dreams etc.

2. Remember: your name just identifies you, it is not you. Your degree is a doorway to a profession, which again is not you. Your materials are only your possessions, which seem to possess many - it is not you. Then who are you? Knowing your texture helps.

3. Know the importance of aligning yourself (values/ thoughts/ thinking/ beliefs/ attitude/ perspectives). Positive alignment gives a purpose, which helps bridge your potentials to your possibilities…

4. Be aware of your words, actions, manners and behaviours, to understand your perspectives and beliefs - these shape your life.

5. Regularly question your beliefs, evaluate your perspectives, analyse your thinking pattern, be aware of your thoughts - you will be able to keep progressing with productive habits, and shape your situations to create the required circumstances. Circumvent problems by connecting with your highest self, prevent problems by responding with a sense of urgency.

6. Realise the power of thoughts & thinking, and how it impacts your life! Symphony among the heart, head & hands, have a profound impact. The collective energy flow from the mind, the powerhouse, is smooth.

7. Become more expressive and explicit in your communication skill. Enhance & raise yourself from telling to talking, then speaking to communicating and finally, from persuading to influencing! Raising your levels within, helps motivate & tap into people around, while helping in inter-personal relationships too. Not labels without but levels within help.

8. Learn how to make life and work a game and enjoy it too - it also helps keep stress & tension at bay. Be aware of the realities - Life Style vs Life itself! Contemplate over better ways to manage self, people, situations and overall life. Having consistency in life is vital. Find out what are the areas to be aware of?

9. Choose to live with happiness & tranquillity - vibrating with positive energy to lead self and others around.

10. Approach is the magic wand which helps in having a pleasant life: 1. Agree to Disagree, 2. Respect Impossible Situations, 3. Find Facts not Faults, 4. Let Go: Respond and not React, 5. Don't ask people WHY, ask WHAT and even better HOW, 6. Interact with Win-Win in mind, 7. Adapt, better than just Adjust

11. Understand what it means to work in groups, teams & to collaborate! It could bring about a big change in your life! 'Ubuntu - I am because you are!' We are all waves in this ocean of existence. Sublimate Ego for best impact. Man has no upper limit.

Fostering Pharmaceutical Excellence

Anila K
Principal
College for Leadership and HRD
Mangalore

Nobody Can Destroy Your Self – Esteem

"I have never seen a more hopeless person than you"

"Is this the way to do it?"

"Look at your face, it's full of pimples and you look ugly"

"Did you not get a better dress to wear?"

"You don't know even after doing it several times"

These perhaps are some of the milder samples of comments people pass on others. Audacious indeed, some would say. Thoughtless indeed, some others would say. Ignorance indeed, yet others would say.

Most people fall into this category of commentators.

It could be your parent, teacher, friend, spouse, boss, colleague, relative, or anyone else who would make such comments.

People make statements, a product of sitting in judgment, which are contemptuous primarily because they don't have competence in communicating and secondly because they have contempt for others. The victim can get hit in such a way that the person MAY lose estimation of one's own self if she is not STRONG enough.

It will be worthwhile to consider what makes people speak in this way.

While one sees the possibilities of their incompetence as one of the prime reasons, one cannot overlook yet another major factor which encourages people to speak in this way. It is the tolerance and decency of people or most of the times helplessness of the individual that enables, rather empowers some people to speak with contempt for the others.

A child is always helpless when comments are made by teachers.

A son or a daughter is most of the time helpless when parents speak in derogatory manner, however good the intentions may be.

Usually a wife, sometimes even a husband, is at the receiving end when caustic remarks are made by the spouse.

Many think that the boss always has THE right to scold or rebuke as he or she is the giver, clearly forgetting that giving is done only because work has been done. Nobody gives before the work is done. Payment is always after the work is done and it is done with such aplomb making the receiver believe that he or she has been fortunate enough to receive it. WHAT AUDACITY.

Usually those from the economically weaker sections, children and women, not necessarily in the same order, are at the receiving end. As said earlier it is the vulnerability and the helplessness that emerges out of it that make another individual to be inconsiderate towards the others and get away with it.

Humour is yet another way employed by some to put down others. In the garb of humour, the victim is ridiculed and made to feel small. There is a very thin demarcating line between humour and ridicule. Usually the victim, unless he or she is very sensitive and also sensible, will not even

know that she or he is being ridiculed. It also happens most of the time that, ridicule is resorted to by a person on whom the victim has a lot of faith. That is how most of the husbands get away because a wife would never want to believe that she is being ridiculed.

There are also other factors that contribute to the way some people belittle others. Sense of superiority is a factor that makes an individual to be contemptuous of others. One could be richer or stronger or better looking or more intelligent which does not mean that one should be contemptuous towards others. Yet, some do so.

Finding fault is another method at one's attempt to make the other person feel small. People in power, superiors so to say or sometimes those aided by superiors, colleagues, sometimes even subordinates, take pleasure in finding fault with others.

Men, many of them, get away by making unwelcome remarks about a woman's body system. Absolute lack of respect for women is responsible for this.

Whether it is by using humour or ridicule or because of a sense of superiority or by finding fault, whenever a person resorts to make another individual feel small, it only shows how small THE former is.

No individual with strong self- esteem will try to make another person feel small. It is only one with a feeling of inadequacy that makes a person resort to such methods where she or he will try to humiliate another individual.

It is sad that such people are in a sorry state of affairs and offer the same in a different way to those who are associated or involved. Hence, it is necessary that instead of getting angry at the comments made, instead of feeling small, people at the receiving end should actually feel sorry for such SMALL people for their tragic state of mind. Such feelings will give confidence to them for their own worth.

And this is applicable to anybody and everybody, be it a parent, a teacher, a friend, a spouse, a boss, a colleague, a relative or anyone else.

People who have faced any number of tragedies in life, who have been persecuted by their own kith and kin, who have faced ridicule despite all the love and respect given, have still learned to walk around with their head held high simply because of the strength of their own self. They work with or interact with others with a strong self - esteem

It simply means that if they can, then anybody can.

Nobody can destroy your self - esteem

Anuradha H V
Associate Professor
Department of Pharmacology
M S Ramaiah Medical College, Bangalore

Role of Pharmacist in Pharmacovigilance

Drugs which are currently available in the market have changed the management of diseases. In spite of occurrence of variety of illness due to change in the lifestyle and food habits, advancement in medical science and clinical research is successful to cure the disease too. There is no single drug with complete safety. Most of the time, multiple drug prescription are used to treat the diseases. Hence, polypharmacy is the most common predisposing factor to the occurrence of adverse drug reactions (ADRs) in a patient. Other factors which contribute for developing ADRs are multiple disease, age, drug characteristics, gender, race and genetics.

Monitoring the safety of these drugs is an integral part of clinical practice. In order to provide effective and good quality health care, safety monitoring is equally as important as the effective use of medicines. To monitor the safety of these drugs consumed by the people, new discipline evolved known as Pharmacovigilance.

Pharmacovigilance is derived from Greek and Latin words; Pharmakon (Greek), "drug" and vigilare (Latin), "to keep awake or alert, to keep watch". The World Health Organization (WHO) defines pharmacovigilance as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems". World Health Organization (WHO) defines an adverse drug reaction (ADR) as "Any response to a drug which is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease or for modification of the physiological function". The terms "Adverse Drug Reaction" and "Adverse Drug Event" are not synonymous. WHO definition of an adverse event is "any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment".

Approval for a medicine is given by the regulatory bodies after controlled and regulated clinical trials. Once an approved medicine is placed on the market, it leaves the controlled scientific environment of clinical trials. At this point, most medicines will only have been tested for short-term safety and efficacy on a limited number of carefully selected individuals. Therefore, it is important that the use of these medicines is monitored for their ongoing effectiveness and safety. Pharmacologists and pharmacists have an important responsibility in monitoring the ongoing safety of medicines. As we are aware, pharmacists increasingly provide management of medication therapy through dispense of pharmaceutical products like drugs as a part of their professional practices. It is a significant advantage to the surveillance of medicines that the pharmacist practitioner is able to provide a patient's complete medication history.

Indian Scenario:

Though adverse drug reaction monitoring system was proposed in India in the year 1986, actual activity started when India joined hands with WHO ADR monitoring programme based in Uppsala, Sweden in 1997. Later, the National Pharmacovigilance Program established in January 2005, was to be overseen by the National Pharmacovigilance Advisory Committee based in Central Drugs Standard Control Organization (CDSCO), New Delhi. To further support NPP, implementation of schedule Y has made it mandatory to report all serious adverse events including suspected unexpected serious adverse reactions.

CDSCO, Directorate the General of Health Services under the aegis of Ministry of Health & Family Welfare, Government of India in collaboration with Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi has launched the nation-wide pharmacovigilance programme for protecting the health of the patients by assuring drug safety. The programme is coordinated by the Department of Pharmacology at AIIMS as a National Coordinating Centre (NCC). The centre will operate under the supervision of a steering committee.

Indian Pharmacopoeia Commission (IPC) is functioning as National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI) since 15th April 2011 under the aegis of Ministry of Health & Family Welfare, Government of India. The major functions of NCC are to collect, collate and analyze ADRs data to arrive at an inference to recommend regulatory interventions to CDSCO , besides communicating risks to healthcare professionals and the public through PvPI Newsletters. In order to collect the ADRs from patients ADRs monitoring centres (AMCs) are set up under NCC. ADRs collected in the AMCs are uploaded to NCC through WHO-UMC owned online software *Vigiflow*. The rationale for setting up the AMCs is to make it possible to identify rare ADRs that could not be found through clinical trials.

The objectives of the PVPI are as follows:

- To monitor Adverse Drug Reactions (ADRs) in Indian population
- To create awareness amongst health care professionals about the importance of ADR reporting in India
- To monitor benefit-risk profile of medicine
- Generate independent, evidence based recommendations on the safety of medicines
- Support the CDSCO for formulating safety related regulatory decisions for medicines
- Communicate findings with all key stakeholders
- Create a national centre of excellence at par with global drug safety monitoring standards

The mission of Pharmacovigilance is to contribute to the protection of public health in the regulation of the safety quality and efficacy of medicines for human use and to ensure the healthcare professionals and patients have access to information about the safe and effective use of medicine. Our current ADR reporting system involves a more or less passive approach in which healthcare professionals are encouraged to report adverse events to the AMC through suspected adverse drug reaction reporting form. Health care professionals who can report ADRs are doctors, dentist, pharmacist and nurses. Now, PvPI has given a provision for the customers to report the ADR through medicines side effect reporting form (for customers) or can call toll free phone number.

There are various methods to carry out the pharmacovigilance activities. It can be achieved through passive surveillance, stimulated reporting, active surveillance and observational studies. Passive surveillance includes spontaneous reporting, case reports, and case series. Stimulated reporting refers to on-line reporting of an adverse events and systematic stimulation of reporting of adverse events based on a pre-designed method or may be using mobile applications. Active surveillance can be done by reviewing medical records or interviewing patients and/or physicians in a sentinel sites to ensure complete and accurate data on reported adverse events; it can also be drug event monitoring where patients might be identified from electronic prescription data or health insurance claims and outcome information is collected through follow-up questionnaire. Another method of active surveillance is through registries which could be drug registry or disease registry. Observational studies are useful in validating the signals generated by passive surveillance; and these studies can be cross-sectional studies, case-control studies and cohort studies. Other modalities which can contribute are descriptive studies and targeted clinical investigations.

Pharmacist's role:

The current role of the pharmacist in post-marketing monitoring is not confined to ADRs and other drug-related problems reporting, but also in the introduction of generic or therapeutically equivalent medicines, reviews of older medicines as well as traditional, complementary and alternative medicines, non-prescription medicines, blood products, biologicals, medical devices and vaccines.

An important clinical responsibility of the pharmacist is in the early detection of ADRs and other drug-related problems as well as monitoring the effectiveness of medicines. The pharmacist, as a part of the healthcare team, is a source of both information and critical evaluation of drug information. The pharmacist's expertise along with clinician and pharmacologist is vital to the application of the safety profile of a medicine to the needs of a particular patient.

An effective approach in pharmacovigilance requires the use of modern informatics. Pharmacists are a key part of the post-approval environment. Also, pharmacists can provide early detection of new ADRs and other drug related problems and identify certain patient subgroups with exceptional sensitivities.

Pharmacists play two important roles as the key health professional for effective pharmacovigilance programmes: as an Educator and Practitioner.

Pharmacist Educators should ensure that the curriculum include the pharmacist's importance in pharmacovigilance. The contribution of the pharmacist and the pharmacy profession should also include the various pharmaceutical disciplines that enhance the understanding of the nature of safety of medicines.

Pharmacist practitioners should understand their pivotal role in the surveillance of the safe use of medicines. The pharmacy profession should acknowledge and promote this role of the pharmacist in the detection and reporting of suspected ADRs and otherdrug-related problems.

Pharmacists need to be actively involved in the surveillance of drug safety issues within the context of their practices. Greater participation by pharmacist practitioner in all practice settings would be an important tool to increase the reporting of ADRs and other drug-related problems. The pharmacist's role in pharmacovigilance varies from country to country, but the professional responsibility is the same regardless of jurisdiction.

Pharmacists Associations should conduct regular programmes of pharmacovigilance in order to provide a method for reporting that is concise, electronic and compatible with pharmacy practice; promotion to consumers and prescribers and acceptance of the pharmacovigilance activities for continuing education and continuing professional development requirements.

The Pharmacists role never ends in detection and monitoring of ADRs. Reporting completes only after the causality assessment of that particular ADR is done to ensure whether any temporal association exist between an ADR and the drug. Causality assessment has to be done by the pharmacist in discussion with pharmacologist and clinician using WHO-UMC assessment scale. Completed quality reporting of ADRs can give a direction in generating a signal. Signal is reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually, more than a single report is enquired to generate a signal, depending upon the seriousness of the event and the quality of the information. The publication of a signal usually implies the need for some kind of review or action. When a signal is detected, further investigation is warranted to determine whether an actual causal relationship exists. Signal management process includes the following activities: signal detection, signal validation, signal confirmation, signal analysis and prioritization, signal assessment and recommendation for action.

In clinical care, Pharmacists are one of the major stakeholders along with the physicians, Pharmacologists, patients and other healthcare professionals. Pharmacists play a key role in management and prevention of the adverse events associated with the drug. At the same time, pharmacists should realize clinical pharmacy is not just drug-drug, drug-food interaction, but it is also tracking adverse drug effects, reducing medication errors, monitoring patients' compliance and counseling of patients.

References:
1. WHO, "The Importance of Pharmacovigilance, 2002"
2. FIP Statement of Professional Standards: Pharmaceutical Care, 1998
3. FIP statement of policy : the role of the pharmacist in pharmacovigilance, 2006
4. SK Gupta. Textbook of Pharmacovigilance, 2011.

Brahmeshwar Mishra &
Sarita Kumari Yadav
Department of Pharmaceutics,
IIT - BHU, Varanasi

Recent Advances In Pharmaceutical Packaging Technology

Packaging plays key role in efficient dissemination of intact pharmaceutical product from manufacturer to the patients. Ideally, packaging is a multi-faceted task which involves containment, presentation, protection, identification / information, convenience and compliance for a product during its storage, transport, marketing and application till its shelf life is attained (1). In today's scenario packaging engineering is growing progressively in pharmaceutical field. Therefore, serious attention is required towards fulfillment of all packaging functions from protection of products to its marketing and use.

Container closure systems are the sum of the packaging components that hold and protect the contained dosage form. It includes primary packaging components (immediate pack in contact with product) and secondary packaging components (add protection to the primary pack) together. The pharmaceutically accepted materials for designing packaging of pharmaceuticals include glass, plastic, metals and rubber, paper each of which has some pros and cons.

Interaction between packaging and products is possible depending on container material and product constituents (drug, excipients and solvents). The kind of packaging materials used must be chosen in such a way that the packaging itself does not have any adverse effect on the product due to leaching and migration of materials and vice-versa. Packaging must protect product against all adverse external infuences i.e. moisture, light, oxygen and temperature variations including biological contamination that can alter the properties of the product (2,3).

In addition to economical and profitable the package should be patient compliant also. The consumer wants packaging to be lighter, easy to handle, aesthetic and safer hygienically. Special attention is required towards packaging of parenterals. Containers and closures for parenterals should be non-shedding, non-reactive with products and must allow withdrawal of contents without any contamination (2). Therefore, selection of ideal package depends on requirements of product (stability, safety, pack and content compatibility), patient (convenience, dosing regimen, route of administration), manufacturing (economical, less time consuming, small size), and market (handling, distribution and presentation) (4).

With the developments in novel dosage forms, advancements in novel packaging are the need of the hour to keep pace with the highly competitive market. In this trends, child resistant, tamper resistant and compliance packaging have emerged.

Child resistance (CR) packaging is desirable for highly potent drugs with improved peel ability and printability which prevent children from accessing the product contents. For instance, an award of 'Most Innovative Child Resistant Packaging Design' was won by Burgopak Healthcare & Technology (UK) for the sliding CR blister pack which can only be opened by applying pressure to two particular separate points (5).

Tamper resistant or evident packages reveal the tampering of product to the consumers and prevent its adulteration. FDA (US) approved inherent tamper resistant packaging

includes film wrappers, blister package, strip package, bubble pack, shrink seals and bands, breakable caps, sealed tubes, aerosol containers, sealed cartons, tape seals, bottle seals, foils and paper or plastic pouches (6). Polyvinylchloride, a heat shrink polymer is used to prepare tamper evident heat shrink wrapper which once cut cannot be reapplied without visible damage to the product. Further, lithographic technique has been developed where the label is directly imprinted on the container which prevents its removal and substitution (6).

Compliance packaging is 'smart novel packs' which maintain compliance of patients to the therapy by increasing their interest in the treatment schedule. They are generally supplied for one treatment cycle in blister packages. It is more beneficial to old patients suffering from cognitive impairment and to those who are taking large number of medication and chances of missing dose is higher (7). They are fabricated in such a manner that they are easy to remember with easy-to-read labels, easy-to-open tear pouches, and additionaly medications are arranged by date and time for 30, 60, 90 day supply. In 2010, Novartis Pharmaceuticals Corporation's won the award of Compliance Package of the Year for Diovan HCT® Shellpak®. This 30 day blister pack is contained in outer Shellpak™, a patented child resistant package (8). SureMed™ by Omnicell® and The Silenor® Patient Starter Kit by Somaxon Pharmaceuticals, are some of the novel compliance package designs (8,9).

Some of the innovations are Holographic induction Cap seals, child resistant containers, geriatrics packs, compliance pack, light weight containers, Radio Frequency Identification (RFID), blister packs of liquid orals as unit dose, and smart packs having time or temperature based indicators (anticounterfeiting) (10).

WHO and other organizations are promoting use of ecofriendly packages which are biodegradable, recyclable and reusable. Ecoslide RX is an eco friendly packaging designed by Keystone Folding Box Company and Legacy Pharmaceutical Packaging. The pack is made up of unbleached paperboard and a clay-coated surface which is 100 % recyclable. Further, this pack is child resistant and economical (11).

FDA, ISO and WHO have provided standards for pharmaceutical packaging designs and materials which should be strictly followed. Advancement in research for pharmaceuticals development had always being complemented by the pace in packaging technology development. Innovations in packaging technology are at growing stage for the development of packages that are more economical, eco friendly and user friendly with high performance.

References

1. Gad SC. Pharmaceutical manufacturing handbook: Production and Processes. John Wiley & Sons, Inc., Hoboken, New Jersey.
2. Guidelines on packaging for pharmaceutical products©. WHO Technical Report Series, No. 902, 2002, Annex 9.
3. Guidance for industry container closure systems for packaging human drugs and biologics, US, 1999.
4. Zadbuke N, Shahi S, Gulecha B, Padalkar A, Thube M. Recent trends and future of pharmaceutical packaging technology. J Pharm Bioall Sci, 5,98-110, 2013.
5. http://burgopakhealthcare.com//02/burgopak-awarded-the-most-innovative-child-resistant-pack-design-at-pharmapack-paris-/Burgopak
6. www.fda.gov/ICECI/ComplianceManuals/.../ ucm074391.htm
7. http://www.echospecialty.com/pages/Compliance/CompliancePackaging.html
8. http://www.hcpconline.org/compliance-prompting-packaging.html
9. https://www.mts-mt.com/Products and Solutions For Pharmacy/Medication Packaging/Multimed/Multimed Standard.aspx
10. Edwards LD, Fletcher AJ, Fox AW, Stonier PD. Principles and practice of pharmaceutical medicine. Second Edition, JohnWiley & Sons Ltd, England.
11. http://www.popularmechanics.co.za/sci-tech-news/nfc-aid-for-the-visully-and-hearing-impaired/

Darshan Raj C G
Dept. Chemistry
PA College of Engineering, Mangalore

Recent Trends in Drug Discovery Research

Introduction

Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. The practice of the drug discovery process has been revolutionized with the involvement of some newer techniques. Target based drug design is more advantageous, time consuming and effective. With the use of High Throughput Screening (HTS) technique, a large number of compounds are screened for their biological activity with the discovered target, which are synthesized by combinatorial chemistry, these are called hits. Quantitative Structure Activity Relationships (QSAR) constitutes immense importance in discovering new drug candidate called analogues which shows high affinity with the target. Various advanced techniques and modern research disciplines such as genomics, proteomics, metabolomics, chemogenomics, and others improve the quality of the drug discovery process.

The progress of Drug Discovery.

In 1865, August Kekule formulated his pioneering theory on the structure of aromatic organic molecules. This benzene theory gave a decisive impulse to research on coal-tar derivatives, particularly dyes. In turn, the evolution of dye chemistry had a profound influence on medicine. The selective affinity of dyes for biological tissues led Paul Ehrlich (Fig. 1), a medical student in the laboratory of the anatomist Wilhelm Waldeyer (between 1872 and 1874) at the University of Strasbourg, to postulate the existence of "chemoreceptors." Ehrlich later argued that certain chemoreceptors on parasites, microorganisms, and cancer cells would be different from analogous structures in host tissues, and that these differences could be exploited therapeutically. It was the birth of chemotherapy, a particular type of drug therapy, that in the course of the 20th century led to unprecedented therapeutic triumphs. Analytical chemistry, in particular the isolation and purification of the active ingredients of medicinal plants, also demonstrated its value for medicine in the 19th century. In 1815, F. W. Serturner isolated morphine from opium extract Papaverin was isolated in 1848, but its antispasmodic properties were not discovered until 1917. As active ingredients from plants became available, many pharmacies addressed the problem of providing standardized preparations of these often still impure drugs.

Pharmaceutical Chemistry in Drug Discovery and Novel Drug Delivery System

Drug discovery is the core of pharmaceutical chemistry. The drug discovery process includes all the stages of drug development, from targeting a disease or medical condition to toxicity studies in animals, or even, by some definitions, testing the drug on human subjects. Typically, conditions that affect a larger percentage of the population receive more attention and more research funding. Antiulcer drugs and cholesterol - reducing agents are currently the therapeutic areas of greatest emphasis. To develop a drug to target a specific disease, researchers try to understand the biological mechanism responsible for that condition. If the biochemical pathways leading up to the diseases are understood, scientists attempt to design drugs that will block one or several of the steps of the disease's progress. Alternatively, drugs that boost the body's own defense mechanism may be appropriate. How do chemists "discover" drugs? Often there is an existing remedy for a condition, and scientists will evaluate how that drug exerts its actions. Once the drug's structure is

known, the drug can serve as a prototype or "lead compound" for designing more effective therapeutic agents of similar chemical structure. Lead compounds are molecules that have some biological activity with respect to the condition under investigation. However, the lead compound may not be effective in combating the disease, or it may produce undesirable side effects. Lead optimization involves chemical modifications to the lead compound to produce a more potent drug, or one with fewer or decreased adverse effects. Computers have transformed the drug discovery process.

Rational drug design involves computer-assisted approaches to designing molecules with desired chemical properties. Rational drug design is based on a molecular understanding of the interactions between the drug and its target in biological systems. Molecular modeling software depicts three-dimensional images of a chemical. Mathematical operations adjust the positions of the atoms in the molecule in an attempt to accurately portray the size and shape of the drug, and the location of any charged groups. Chemists can vary the atoms or groups within the model and predict the effect the transformation has on the molecular properties of the drug. In this way, new compounds can be designed.

Advances in technology have made it possible for medicinal chemists to synthesize a vast number of compounds in a relatively short time, a process referred to as combinatorial chemistry. In this technique, one part of a molecule is maintained, as different chemical groups are attached to its molecular framework to produce a series of similar molecules with distinct structural variations. Combinatorial libraries of these molecular variants are thus created. Every chemical that is synthesized must be tested for biological activity. *In vitro* testing involves biological assays outside a living system. For example, if the desired effect of a drug is to inhibit a particular enzyme, the enzyme can be isolated from an organ and studied in a test tube. New technologies have made it possible to assay large numbers of compounds in a short period. High-throughput drug screening allows pharmaceutical chemists to test between 1,000 and 100,000 chemicals in a single day! A compound that demonstrates some biological activity will undergo further tests, or it may be chemically modified to enhance its activity. As a consequence, chemical libraries consisting of potentially therapeutic compounds are developed. Each of these compounds can then serve as leads for the development of new drugs to be screened. Once a drug shows promise in vitro as a therapeutic agent, it must also be screened for toxic properties. Adverse drug side effects are often due to the interaction of the drug with biological molecules other than the desired target. It is very rare that a drug interacts with only one type of molecule in a living system. Drug selectivity refers to the ability of the compound to interact with its target, not with other proteins or enzymes in the system.

To investigate drug toxicity, animal studies are performed. These studies also estimate mutagenicity, that is, whether the compound under investigation damages genetic material. Rarely does a drug pass through a biological system unchanged. Most drugs undergo chemical transformations (in a process known as drug metabolism) before they are excreted from the body. The drug transformation products (metabolites) must be identified so that their toxicological profiles can be determined.

Combinatorial Chemistry in Drug Discovery

Combinatorial chemistry is a sophisticated set of techniques used to synthesize, purify, analyze, and screen large numbers of chemical compounds, far faster and cheaper than was previously possible. The direct precursor of combinatorial chemistry was the solid-phase synthesis of polypeptides developed by American biochemist Robert Bruce Merrifield in the 1960s, followed by the advances in laboratory automation since then. Initial development of the field has been led by the pharmaceutical industry in the search for new drugs, but its applications are spreading into other fields of chemistry. Other terms associated with this field are parallel array synthesis and high-throughput chemistry. Whereas classical synthetic chemistry involves the stepwise synthesis and purification of a single compound at a time, combinatorial chemistry makes it possible to synthesize thousands of different molecules in a relatively short amount of time, usually without the intermediate separation of compounds involved in the synthetic pathway, and with a high degree of automation. Such procedures result in the production of new compounds faster and in greater numbers than is possible with standard synthetic methods. The first and still the most common type of combinatorial synthesis involves attaching a molecular species onto a macroscopic substrate such as a plastic bead and performing one or several well-characterized chemical reactions on the species. After each reaction, the product mixture can be split among several reaction containers and then recombined after the reaction (a procedure called mix and split), or else carried out in parallel containers. The resulting mixture of compounds is referred to as a molecular library

and can contain many thousands of individual compounds. The analysis, or screening, of these libraries to identify the compounds of interest, along with their subsequent isolation and identification, can be completed by a variety of methods. One example is iterative deconvolution; it involves the successive identification of each of the units backward along the chain of synthesized units. Another, called positional scanning, requires the multiple synthesis of a library, each time varying the location of a known unit along the chain and comparing the activities of the resulting libraries. More recent advances in library screening involve the "tagging" of a substrate with tiny radio frequency transmitters or unique two-dimensional barcodes. Another important recent advance by researchers allows combinatorial syntheses to be carried out in solution, which further extends the scope and utility of this field.

Since 1990s, the drug discovery process has been revolutionized with the introduction of some newer techniques in molecular biology, biotechnology, genomics, and bioinformatics. Very High expectations from newer trends in drug discovery due to its speed, cost, and greater success. High Throughput Screening (HTS) is a powerful technique which speedup the screening process. Target oriented development is a plus point, and receptors especially G-protein coupled receptors (GPCRs) has been successfully targeted. Despite all this, there has been a steady decline in the number of new drugs and still drug discovery a lengthy, expensive, difficult and inefficient process with low rate of new therapeutic discovery.

References

1. Athar Mohd and Das Amar Jyoti , Current trends in drug discovery: target identification to clinical development of the drug IRJP (2012), 3 (4)

2. Fishburn C.S., Translational research: the changing landscape of drug discovery, Drug Discov Today (2013)

Ganesh K
Principal Scientist, Indian Veterinary Research Institute Bangalore
Nominee Member, Committee for the Purpose of Control and Supervision on Experiments on Animals

Ethical issues in Animal Experiments

The use of animals in research and development is justified by the utility for humans because of the concept "good for the greater". This is the basic principle of utilitarian ethics which follow the proper course of action is the one that maximises utility.Experimentation on animals in research and education is coveredby provisions of the Prevention of Cruelty to Animals Act, 1960 and Breeding of and Experiments on Animals (Control & Supervision) Rules of 1998, 2001 and2006 framed under the Act. The CPCSEA is a statutory Committee, which is established under Chapter 4, Section 15(1) of the Prevention of Cruelty to Animals Act 1960. India is one of the pioneering countries to institute Prevention of Cruelty to Animals Act in 1960.

CPCSEA (Committee for the Purpose of Control and Supervision on Experiments on Animals)

The rules and guidelines are enforced by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), a statutory body under the Prevention of Cruelty to Animals Act, 1960. The concerned establishments are required to get themselves registered with CPCSEA, form IAEC, get their Animal House Facilities inspected, and also get specific projects for research cleared by CPCSEA before commencing the research on animals. Further, breeding and trade of animals for such experimentation are also regulated under these Rules. In an amendment bought out in 2006 in the Rules for Breeding of and Experiments on Animals (Control & Supervision), powers to permit experiments on small animals were given to Institutional Animal Ethics Committee (IAEC) of the establishments. Only proposals for conducting experiments on large animals are required to be sent to CPCSEA for approval.

The objective of CPCSEA is to ensure that animals are not subjected to unnecessary pains or suffering before, during or after performance of experiments on them.
The main functions of CPCSEA are:

1. Registration of establishments conducting animal experimentation or breeding of animals for this purpose.

2. Selection and assignment of nominees for the Institutional Animal Ethics Committees of the registered establishments.

3. Approval of Animal House Facilities on the basis of reports of inspections conducted by CPCSEA.

4. Permission for conducting experiments involving use of animals.

5. Recommendation for import of animals for use in experiments.

6. Action against establishments in case of established violation of any legal norm/stipulation.

7. Conduct of Training Programmes for the Nominees of CPCSEA.

8. Conduct / Support of Conference / workshop on Animal Ethics.

The guiding principles underpinning the humane use of animals in scientific research are called the 3 Rs (REDUCE, REFINE OR REPLACE THE USE OF ANIMALS). Any researcher planning to use animals in their research must

first show why there is no alternative and what will be done to minimise numbers and suffering, i.e.

- Replace the use of animals with alternative techniques, or avoid the use of animals altogether.
- Reduce the number of animals used to a minimum, to obtain information from fewer animals or more information from the same number of animals.
- Refine the way experiments are carried out, to make sure animals suffer as little as possible. This includes better housing and improvements to procedures which minimise pain and suffering and/or improve animal welfare.
- There should be science based approach toreduce, refine or replace the use of animals and economic & scientific considerations in all animal welfare activities.
- Animals use - cannot be totally avoided, Biologicals production require small number of animals for primary cell cultures, antibodies production. Quality control and Potency testing in target species involves use of small numbers of animals for, safety testing,

Harm Benefit analysis:

A harm-benefit analysis in which the potential benefits of a research project are weighed against the harms likely to be caused to animals - whether done by the competent authority or by an ethics or animal care and use committee - forms the basis of ethical frameworks. Under the Harm Benefit analysis, experimenter need to address the following,

- Describe the specific elements of the method that ensure that the animals utilized in this protocol are subject to the least possible harm given the parameters of the study.
- Describe the specific benefit you anticipate achieving from conducting this method (these may include drug discovery/ development, drug/chemical safety, the refinement of technique, etc.)
- Define or describe briefly, how the established humane end points are defined within the method.
- What is the earliest end point that would satisfy the scientific objective of the study?
- What specific signs/symptoms will be looked for in assessing possible pain and distress during the study used to assess the point of study termination?
- If the protocol consider "death as an endpoint", provide scientific justification for allowing the animals to pass and through the moribund stage without considering euthanasia.

A legal and ethical obligation for all of us

- To have a humane regard for animals,
- To prevent as far as possible any pain & distress,
- To be constantly aware of the possibilities of achieving the same result without using living subjects.
- An expert veterinarian in laboratory animal sciences should be responsible for animal health care.
- Animal caretakers and animal technicians involved should have proper training in disease models, as well as with signs of pain, suffering and distress.



Harsha Doddihal, MD
CEO & Co-Founder
Right Care - A Unit of Prana Healthcare Enablers

Improving Quality of Life

Human beings have to a large extent taken care of food, clothing and shelter. Whether there is floods or drought, we ensure that food supply is available to the majority. We still have people who die because of hunger or cold weather but that is gradually decreasing. This is the progress which the world boasts about.

Once, we have taken care of the basic needs, we start focussing on quality of life. The quality of life differs from nation to nation and in the same nation, between different strata of society.

All the innovations ranging from cell phone, good roads, to air travel have made life better. The pharmaceutical industry along with healthcare industry can boast that it has saved lives. The average life span has consistently increased for the last 100 years.



Life expectancy gains because of pharmaceutical innovation is provided below.



New Cancer Therapies: More Survivors

As we start to live longer the concept of quality of life becomes very important. Living longer can be a blessing only when the quality of life is good if not excellent.Many clinical trials measure quality of life as a secondary endpoint. But we may need to do more.

Quality of life gets enhanced when people get human touch. Elderly feel the need to be valued, connected and respected. All this is possible when we "listen". Listening is more than hearing. Most of the times our communication is limited to providing established answers without understanding the need of the person. Listening involves empathy and compassion. When we "listen", we create solutions which improve the quality of life.

Doctors, pharmacists, nurses, caregivers all need to be constantly trained and reminded in the art of listening to improve outcomes for our patients. One such outcome would be medication adherence. Medication adherence can be as low as 15% to 50%. This outcome can be improved by listening to our patients and solving the reason for nonadherence.

We wish to highlight that community as well as hospital pharmacists have a great role in improving medication adherence and thereby improving the lives of patients.

How can pharmacists improve quality of care and thereby improve quality of life?

According to a report by Fiercepharma :

1. **Medication management:** Pharmacists can play a role helping patients with chronic diseases have better medication adherence and clinical outcomes.

2. **Medication reconciliation:** Pharmacists help detect and reduce medication discrepancies and increase benefits through comprehensive transition of care programs, especially among postdischarge patients with an elevated risk of readmission.

3. **Preventive care services:** Pharmacists play a key role in immunization services and identifying vaccine candidates. They also provide screening services, and have great access to the community.

4. **Education and behavior counseling:** Pharmacist provided behavioral counseling improves medication adherence and therapeutic outcomes in patients with chronic conditions, and can play a major role in other types of pharmacist interventions shown to improve outcomes.

5. **Collaborative care models:** Team based care that includes pharmacists improve outcomes among patients with chronic conditions, and can alleviate demand for physician provided care, as well as give access to primary care services related to medication management.

Summary: Healthcare professionals including pharmacists will have to be cognizant of the challenges of polypharmacy and the impact it can have on the quality of life. Taking an active role in preventing and managing ill effects of nonadherence, drug-drug interactions, potential side effects because of reduced metabolism in old age can improve the quality of care of individual patient.

Cure For Cancer New Hope?

To cure cancer will be an achievement of greatest order for human beings. Cancer has challenged many researchers, scientists and nations from time immemorial. We live with the hope that curing cancer will be as easy as treating common cold, in few years from now. But there are many things which we have achieved till today which need to be highlighted. Death rates for cancer have been declining especially in the developed countries.





Image Courtesy: GLOBOCAN

The above graphs depict that the cancer mortality after peaking around 1990's has been gradually decreasing. This progress has been because of improved imaging, improved surgical and radiation techniques, newer chemotherapeutic agents and molecular advancements .

Cancer is curable if diagnosed and treated early!

But for all the progress, cure still remains elusive for the individual patient. There are good cancers and bad cancers. Pancreatic cancer, Liver cancer, Lung cancer, Glioblastoma Multiforme (Brain Tumor) are all difficult cancers to cure and have very poor survival rates. While as Breast cancer, Prostate cancer, Cervical cancer, Colorectal cancer have excellent survival rates. There are patients who do well in bad cancer group and there are patients who do poorly in the good cancer group. Today we understand that beyond stage and histology, genetic mutations also determine the response to therapy and survival. As a thumb rule, larger the tumor, greater the number of mutations, making it difficult to treat.

Surgery, Radiation and Chemotherapy have difficulty in treating large tumors which have metastasized. Even in small tumors if the number of mutations are large they recur after surgery or radiation and do not respond well to chemotherapy.

What is the hope for patients with such cancers?

Immunotherapy is one such promise for achieving cure of cancer in difficult cases.

What is Immunotherapy?

Cancer cells are fundamentally different from normal cells. Any cell which is not normal or foreign is eliminated by the immune system. So, most of the times our immune system gets rid of cancer cells and we are saved.

Cancer cells which survive and thrive avoid being killed by the immune cells in our body.

How do cancers which grow evade immune system?

These cancer cells masquerade as normal cells, they do so by expressing few surface receptors which are present on normal cells. Seeing these receptors, immune cells get fooled into believing that cancer cells are normal cells.



PD-1 is the receptor present on immune cells (T cells) which helps them identify the foreign/malignant cell.. The normal cells in our body have PDL1 receptor. The binding of Pd1 with PDL1 is more like a handshake which makes the immune cell believe that the cell which sports PDL1 is a friend.

If there is no PDL1, the immune cell attacks that cell and scavenges it. There are many other receptors which help the immune system like PDL2, CTLA4, Bh7.

By hiding or activating these receptors on T cells or the tumor cell , we can make the immune system to attack the cancer cells. Today we have drugs which do that. All patients do not respond to immunotherapy, but those who respond, have response for longer duration. Once primed this way, it is being anticipated that T cells will remember for life and not allow the tumor to come back. This is one way of getting close to the cure of cancer. What better way to stay away from cancer by having our own immune cells primed to eliminate cancer cells!

And, yes, immunotherapy does have its own share of side effects. So, we have a long way to go before we create treatments which do not cause any harm at all but cure us completely.

Further Reading:

1. The T Cell Army http:// www.newyorker.com/magazine/2012/04/23/thetcellarmy
2. The Blockade Of Immune Checkpoints In Cancer Immunotherapy http://www.nature.com/nrc/journal/v12/n4/full/nrc3239.html
3. Immune Checkpoint Blockade In Cancer Therapy http://jco.ascopubs.org/content/early/2015/01/20/JCO.2014.59.4358.full

M V N Kasyap
Motivational Speaker &
Human Excellence trainer, Buoyancee
www.buoyancee.com

Thought a Vaccine or a Toxin: "Ham ko man ki shakti dena man vijaykare"

Just like food is to the body, thought & thinking is to the mind. Just like consumption of un-hygienic food causes physical sickness, un-hygienic thoughts & thinking result into mental sickness.

Most seem to be bothered about their physical health and the food that they eat, what about mental health and mental wellbeing?

If man is the most superior of the species, we should have created 'Heaven on Earth' by now… We have only created comfort and conveniences at the cost of relationships and ecology. And the reason is, man is dis-at-ease, and this epidemic disease, resulting due to comparing, conditioning and criticism, is going unnoticed!

Today, for personal gains, we find mankind polluting water, to gain money fast, we are hooked on to fast foods, which do not give us the vitals, and it is surprising to find adulterated medicines too. The root cause for all this is, the MIND of an individual is being polluted and contaminated, with negativities like greed, jealousy, hatred etc. If this source is addressed, the outside will be taken care of.

A pure & positive thought works like a vaccine, and develops resilience to fight against the odds in life. Unfortunately, circumstances seem to be poisoning many mindswith negative &un-productive thoughts.

We want secure bank accounts, email account have special id's, our face book account is protected from people hacking it;however, our mind seems to be vulnerable to negativity. Today, anybody can hack our mind and drain positivity from us. Question arises, how come people are not aware of the same? Is it because we are conditioned to give more priority to tangibles like marks, money and materials rather than intangibles like happiness, tranquillity, peace of mind etc.???

Green revolution brought us out of food shortage, white revolution flooded India with milk making us the top producer - now it's time for thought revolution.

To make our country better, first we need to make our individuals better. Quality thoughts and thinking anchored to values and morals is the only way forward!

To have clean India, we need to have a clean mind in every individual. Today, our mind seems to have become like amunicipality dustbin. It's time to clean our mind first. As pharmacists, let us see what antidote medicines we can dispense: -

Poisonous thoughts and their anti-dotes:

Poisonous thoughts	Anti-dote
Boredom	Motivation: to pursuesoul oriented goal. Having an attitude of learning and surging ahead.
Being lazy and dull	Enthusiasm: and Energy emanating out of belief in self.
Being casual	Discipline: It is being comfortable in uncomfortable situations.
Procrastination	Inspiration: Purposeful goal with meaningful actions to keep procrastination at bay.
Fear of failures and rejections.	Courage: willingness to take intelligent and calculated risks, and learn from mistakes. Succeeding in LIFE without failure, is just a lie
Disloyal and cheating	Integrity: working to able values,rather than working for valuables.
Comparison and wanting to become someone else	Nurturing: anchoring to uniqueness and being original
Hurting & hating self and people	Empathy: accepting the reality thus, respecting self and others, as they are.

Mahadev Murthy T S, MD
Department of Community Medicine
MVJ Medical College and Research Hospital, Hoskote

Role of Pharmacist with Practicing Physician at Community Set-up

3P's of Patient care



- Pharmacist should have good understanding and rapport with the physician.
- He should supervise the dispensing of medicines to patients
- Advise patients on how their medicines are to be taken or used in safest and most effective way in the treatment of common ailments.
- They have to ensure ethical guidelines to ensure correct and safe supply of medicines to the community.
- They have to dispense the medicines based on the physician's prescription. He should not make any substitution to the prescription without the physician's knowledge.
- He should inform the patients that in case of any adverse effects noticed must be immediately reported to medical officer without any delay.
- Pharmacist has to check the expiry date of all medicines that are stored in pharmacy store as well as before dispensing the medicines.
- He should maintain a drug register to have good inventory control and to ensure continuous supply of medicines to the patients.
- He should know the local language and should have good communication skills to communicate with the local people.
- If he is interested he can work in research and development of medicine and other health related works.

Manjula PS
Department of Chemistry
P A College of Engineering, Montepadavu
Mangalore

Recent Advancement in the Discovery of non-steroidal Anti Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs), also called as nonsteroidal anti-inflammatory agents or analgesics or nonsteroidal anti-inflammatory medicines (NSAIMs), are a class of drugs that provides analgesic (pain-killing) and antipyretic (fever-reducing) effects, but in higher doses have anti-inflammatory effects. The term nonsteroidal distinguishes these drugs from steroids, which, among a broad range of other effects, have a similar eicosanoid-depressing, anti-inflammatory action. As analgesics, NSAIDs are non-narcotic and thus are used as a non-addictive alternative to narcotics. The most prominent members of this group of drugs, aspirin, ibuprofen and naproxen. Paracetamol (acetaminophen) is generally not considered an NSAID because it has only little anti-inflammatory activity. It treats pain mainly by blocking COX-2 (cyclo-oxygenase 2) mostly in the central nervous system, but not much in the rest of the body.

Historically, anti-inflammatory drugs had their origins in the serendipitous discovery of certain plants and their extracts being applied for the relief of pain, fever and inflammation. Years ago the Greek physician Hippocrates prescribed an extract from willow bark and leaves (Willow Spp.,). Later in the 17th century, its active ingredient, salicin was identified in Europe. The Kolbe Company in Germany started mass production of salicylic acid in 1860. This enabled the synthesis of acetyl-salicylic acid or Aspirin. Acetyl-salicylic acid was the more palatable form of salicyclic acid, that was introduced into the market by Bayer in 1899. However, the mechanism of action of anti-inflammatory and analgesic agents such as aspirin and indomethacin remained elusive until the early 1960's. This all changed in the seventies, when John Vane discovered the mechanism of action of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) thereby increasing our ability to develop novel anti-inflammatory therapies. The success of NSAIDs in treating various inflammatory conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA) validated inhibition of the enzyme prostaglandin H synthase (PGHS) or cyclooxygenase (COX) as a highly suitable target in anti-inflammatory therapies. However, the gastrointestinal (GI) toxicities associated with widespread NSAID use proved to be a major drawback during long term therapy. In the early 90's, Needleman, Simmons and Herschman's group reported the presence of an inducible isoform of the enzyme COX later identified as COX-2. This discovery led to the hypothesis that anti-inflammatory prostaglandins (PGs) were produced through constitutive expression of COX-1, whereas the proinflammatory PGs were produced via induction of the COX-2 isoform. The traditional NSAIDs were known to inhibit both isoforms of COX and their adverse GI toxicities were attributed to the inhibition of gastroprotective PGs produced via the COX-1 pathway. Later, scientists from the academic community and pharmaceutical companies focused their efforts on the design of selective COX-2 inhibitors in order to develop superior anti-inflammatory and analgesic agents with reduced adverse effects compared to traditional NSAIDs. In 1999, G.D. Searle and Pfizer (now Pfizer Inc) launched the first selective COX-2 inhibitor celecoxib (Celebrex®). This was followed by the launch of Merck's selective COX-2 inhibitor rofecoxib (Vioxx®). In a short period of time both celecoxib and rofecoxib (coxibs) reached blockbuster status achieving sales exceeding one billion U.S. dollars within 15 months post launch. In spite of this

initial success after the launch of selective COX-2 inhibitors, concerns were raised regarding their adverse cardiovascular events. Further studies, conclusively demonstrated that selective COX-2 inhibitors may tip the natural balance between prothrombotic thromboxane A2 (TxA2) and antithrombotic prostacyclin (PGI2) potentially increasing the possibility of a thrombotic cardiovascular event. In September 2004 Merck's Vioxx® was withdrawn from the world-wide market. In April of 2005, the US FDA advisory committee overwhelmingly concluded that coxibs increase the risk of cardiovascular events and recommended the suspension of Pfizer's Bextra® (valdecoxib). Celecoxib was allowed to remain in the market place, but with a black box warning indicating a risk of adverse cardiovascular events. Furthermore, the FDA requested manufacturers of commonly used NSAIDs to make labeling changes to their products suggesting that adverse cardiovascular events could be a general effect for this class of compounds. The European Medicines Agency (EMA) was in agreement with the FDA regarding the suspension of Bextra® and labeling changes for coxibs. However, the EMA gave a clean chit to traditional NSAIDs based on their benefit to risk ratio. Recently, the American Heart Association issued a statement advising prescribing clinicians pertaining to the use of NSAIDs. Health Canada recently decided to withdraw Novartis Pharmaceuticals selective COX-2 inhibitor lumiracoxib (Prexige®) due to concern regarding its liver toxicity.

Over the last 10 years, discovery of the second isoform of cyclooxygenase (COX-2) has led to the development of specific COX-2 inhibitors and resulted in potent anti-inflammatory compounds with significantly reduced GI toxicity. Additionally, novel compounds have been developed for better-tolerated nonsteroidal anti-inflammatory drugs, by adding a nitric oxide (NO)-releasing group to conventional NSAIDs (NO-NSAIDs), dual COX/LOX (lipoxygenase) inhibitors and anti-TNF (tumor necrosis factor-alpha) therapy. They are used in inflammation, cancer, as well as additional potential therapeutic agents. Discovery of new therapeutic targets to treat a whole range of conditions that were never until now envisaged. In spite of the unprecedented advances in drug discovery, developing a safe, effective and economical therapy for treating inflammatory conditions still presents a major challenge.

References:

1. Praveen P N Rao & Edward E Knaus, Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharmaceut Sci., 11(2), 81s-110s, 2008.

2. Shinichi Kawai, Fumiaki Kojima & Natsuko Kusunoki, Recent Advances in NonsteroidalAnti-Inflammatory Drugs, Allergology International, 54, 209-215, 2005.

3. Highlights of New anti-inflammatory agents: NO-NSAIDs and COX- 2 inhibitors, 11th International conference on advances in prostaglandin and leukotriene research: basic science and new clinical applications, Florence, June 4-8, 2000.

Neelima Dhingra
University Institute of Pharmaceutical Sciences
Department of Pharmaceutical Chemistry
Panjab University, Chandigarh

Computer Aided Drug Design: Tools for Modern Drug Discovery

Introduction

Drug discovery and development are very time and resources consuming processes. Cheminformatics integrates the comprehensive knowledge of chemistry and extensive understanding of Information technology, in order to streamline drug discovery, design, development and optimization. Computer-aided or in silico design is being utilized to expedite and facilitate hit identification, hit-to-lead selection, optimize the absorption, distribution, metabolism, excretion and toxicity profile. Regulatory agencies as well as pharmaceutical industry are actively involved in development of computational tools that will improve effectiveness and efficiency of drug discovery and decrease use of animals, cost and time and increase predictability. The purpose of this paper is to provide the reader with a general overview that coupling computational tools with a rational drug design process has led to the discovery of small molecule as therapeutic agents for numerous human disease conditions and/or have supported their clinical evaluation with some approvals by the Food and Drug Administration. It is expected that the power of CADD will grow as the technology continues to evolve.

"This is a fantastic time to be doing drug discovery. We have an incredible wealth of knowledge that has been generated over the past few years."

Keywords: Drug Discovery; Cheminformatics; CADD; Success stories; Softwares

Drug discovery and development is an interdisciplinary, expensive and time-consuming process. Estimates of time and cost of currently bringing a new drug to market vary, but 12-15 years and multi million $ are often cited. Furthermore, five out of 10,000 compounds tested in animals reach human testing and only one of five compounds reaching clinical studies is approved. This represents an enormous investment in terms of time, money, human and other resources. It includes chemical synthesis, purchase, curation, and biological screening of hundreds of thousands of compounds to identify hits followed by their optimization to generate leads, which requiring further synthesis. In addition, predictability of animal studies in terms of both efficacy and toxicity is frequently suboptimal. Therefore, there was need to develop new approaches to facilitate, expedite and streamline drug discovery and development processes.

Advances in computational techniques and in parallel hardware support have enabled computer aided drug design (*in silico*) methods, to speed up new target selection through the identification of hits to the optimization of lead compounds in the drug discovery process. CADD entails:

- Use of computing power to streamline drug discovery and development process
- Leverage of chemical and biological information about ligands and/or targets to identify and optimize new drugs

- Design of in silico filters to eliminate compounds with undesirable properties (poor activity and/or poor Absorption, Distribution, Metabolism, Excretion and Toxicity, ADMET)

- Select the most promising candidates.

At the beginning of a drug-discovery project, chemoinformatics tools are employed to choose compounds from available sources to be assayed. Some marginally active or better compounds may be found, and then chemical similarity searching techniques are used to find more compounds that should be assayed. If some compounds that are more active are discovered, computationally more expensive techniques are applied, such as docking and pharmacophore modeling, to identify more potent compounds or optimize more ADME/T favorable compounds.

Commonly used computational approaches include combinatorial chemistry; high thought put screening; virtual screening ; ligand-based drug design (pharmacophore, a 3-D spatial arrangement of chemical features essential for biological activity), structure-based drug design (drug-target docking), *de novo* drug design, molecular dynamics simulations, and quantum chemical methods, and quantitative structure-activity and quantitative structure-property relationships; in vitro and in silico evaluation method as shown in figure 1.



Figure 1 Application of CADD at different stages of drug development process

Techniques of CADD also provide other options for understanding chemical systems, which yield information that is not easy to obtain in laboratory analysis, After ups and downs of the perception of CADD in the field of drug development, and perhaps some over-hyping of its promises, especially in the initial phases of new trends in development, one can probably say that the discipline of computational medicinal chemistry has begun to mature and become a realistically assessed and routinely used component of modern drug discovery. During the past two decades, techniques of CADD have changed the way pharmaceutical research generate novel bioactive molecules, and, furthermore, is typically(much) less costly, save time, money and resources, as shown in Figure 2.



Figure 2

Successful Stories

Coupling more sophisticated computer software and hardware technologies with a rational drug design process has become an indispensable tool for the development of effective therapies and in past few years, it has led to the discovery of small molecule therapeutic agents with activity directed against target proteins critical in the presentation of numerous disease conditions and/or have supported their clinical evaluation. Some of the experimental drugs has been discovered and/or optimized using computer-aided drug design.

Successful Stories

Therapeutic area	Experimental status
Antifungals (Group1) Indian Pharma Co.	15 molecules synthesized & 10 active, 3 better efficacy than present drugs
Antifungals: Group 2 (With Indian PharmaCo.)	45 molecules synthesized & 11 high, 13 moderate, 11 inactive
Antidepressant (With a European PharmaCo)	22 molecules synthesized, 10 active
Memory & learning (With a US based PharmaCo)	Synthesis & testing underway
Breast cancer (With Karmanos Cancer Institute, Detroit)	Synthesis of 140 compounds, 5 active

List of Softwares for computer aided drug design

Listed below are some of the companies, software , and other resources related to computer-aided drug design approaches, especially chemical databases and chemoinformatics tools, structure-based drug design, ligand-based drug design:

- (www.acdlabs.com) ACD/Labs - analytical informatics & prediction
- (https://www.cambridgesoft.com) Cambridge soft - 2D/3D drawing tools & E-notebooks
- (https://www.cas.org/) CAS - produce Scifinder Scholar searching software
- (http://www.lionbioscience.com) Lion Bioscience - produce LeadNavigator
- (www.eyesopen.com) Openeye - Fast 3D docking, structure generation, toolkits
- (www.q-pharm.com) Quantum Pharmaceuticals - prediction, docking, screening
- (http://www.scripps.edu/mb/olson/doc/autodock/), Gold" (http://www.ccdc.cam.ac.uk/products/life_sciences/gold/), Dock
- (http://dock.compbio.ucsf.edu/), Insight II Affinity and Cerius2 LigandFit
- (http://www.accelrys.com/), Sybyl including FlexE and FlexX
- Glide (http://www.schrodinger.com/ProductDescription.php?mID=6&sID=6), and MOE
- Vlife MDS; www.vlifesciences.com

Conclusion

R&D in the pharmaceutical industry is undergoing a lot of technological changes, and there is pressure to make the investment pay off. There is a big need to sensibly use the large amounts of chemical and biological-related information produced in the process. Thoughtful use of chemoinformatics methods and software is becoming crucial to the success of drug discovery CADD is an evolving field with many facets. Regulatory agencies as well as pharmaceutical industry are actively involved in development of computational tools that will improve effectiveness and efficiency of drug discovery and development process, decrease use of animals, and increase predictability. It is expected that the power of CADDD will grow as the technology continues to evolve. And Its estimated that computer modeling and simulations account for ~ 10% of pharmaceutical R&D expenditure and that they will rise to 20% by 2016.

REFRENCES

1. www.innovation.org ; 2007
2. I.M. Kapetanovic' "Computer-Aided Drug Discovery And Development (CADD): In silico-chemico-biological approach" Chem Biol Interact. 2008; 30; 171(2): 165-176.
3. Tanaji T. Talele, Santosh A. Khedkar and Alan C. Rigby, "Successful Applications of Computer Aided Drug Discovery: Moving Drugs from Concept to the Clinic; Current Topics in Medicinal Chemistry, 2010; 10; 127-141.
4. Markus Sitzmann, Angelo Pugliese, Chenzhong Liao and Marc C Nicklaus; "Software and resources for computational medicinal chemistry", Future Med Chem. 2011; 3(8); 1057-1085.

S Ramachandra Setty
Professor, Government College of Pharmacy
Bengaluru & Nominee Member, Committee for the Purpose of Control and Supervision on Experiments on Animals

Present Scenario of Indian Pharma Industry and Future Themes for Improving The Employability of Pharmacy Graduates

Pharmaceutical industry in India is growing phenomenally in recent times and reached the stage that it is next to IT sector in the country in terms of volume of production and export. India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines (1).

Presently there are 10,500 manufacturing units and over 3,000 Pharma companies in India, growing at an exceptional rate. India has about 1,400 WHO GMP approved manufacturing units. India has been accredited with approximately 1,105 CEPs, more than 950 TGA approvals and 584 sites approved by the USFDA. Globally more than 90 per cent of formulations approvals for Anti-retroviral (ARVs), Anti-tubercular & Anti-malarial (WHO pre-qualified) has been granted to India.

Manufacturing costs in India are approximately 35-40 per cent of those in the US due to low installation and manufacturing costs. India ranks amongst the top global generic formulation exporters in terms of volume. India's pharma exports stood at US$ 15 billion in 2013-14. India exports all forms of pharmaceuticals from APIs to formulations, both in modern medicine and traditional Indian medicines.

The country's pharmaceutical industry accounts for about 1.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms. India's Pharma sales are expected to reach US$ 27 billion by 2016. India is well placed to become one of the major drivers in providing healthcare to all while controlling the ever-increasing healthcare expenditure of both developed and developing nations (1).

In this context there is a demand for highly skilled Pharma professionals in the country. Several universities, Pharmacy institutions are trying in their own way to produce Pharmacy professionals so as to meet requirements of the Pharma Industry. However there are reports that vast difference exists between the syllabus taught and the requirements of the industry (2). This results in the drastic reduction in the employability of Pharma graduates coming out of pharmacy institutions. In addition there is mushrooming growth of pharmacy institutions in recent times. It is observed that majority of institutions do not have minimum facilities and qualified teachers to teach highly specialized subjects of pharmaceutical sciences and professional skills.

Similarly Hospital pharmacist and community pharmacists role has been changing and is now not merely a person to dispense the drugs. In addition he is also involved in patients counseling, monitoring of drug interactions, monitoring adverse drug reactions and also play a vital role in drug discovery research. Therefore it is essential to

redesign the syllabi of Pharmacy courses at all levels (D.Pharm., B. Pharm., M.Pharm and Ph.D.) so that highly skilled pharmacy professionals has to be prepared to strengthen the health care system of the country.

In this process of improving the pharmacy education, need for consultations with all the stakeholders of the profession like government, academia, industry, experts, students, researchers in the field, etc. This consultation process shall be time framed so that comprehensive Pharmacy education policy may be framed. This consultation process shall be on specific themes. The themes for consultation process are:

01. Governance reforms for quality
02. Improving the quality of regulations
03. Ranking of institutions and accreditations
04. Integrating professional skill development with curriculum
05. Adopting technology enabled learning
06. Linking Pharmacy education with health care system and social needs
07. Involving all stake holders in framing the syllabi
08. Engagement with industry to link pharmacy education to employability
09. Developing quality teachers
10. Inculcating ethical practices in profession
11. Promoting entrepreneurship
12. Promoting research and innovation
13. New knowledge
14. Financing Pharmacy education
15. Sustaining student support systems

Roop K Khar
S Duraivel
BSA Institute of Pharmacy, Faridabad

Peroral Administration of Peptides and Proteins-An Overview

INTRODUCTION:

Reinvigoration is underway in the bulk peptide market, with many bulk peptides producers, reporting industry growth in double digits. Discovery of new peptide molecules, improved formulation, delivery systems, and opportunities in the generic market are contributing to this growth. As therapeutic ingredient "peptides are generally non-toxic, have few side effects and represent the best avenue of therapy for many diseases, when they can be successfully delivered to the target tissue". The high potency of peptides translates into small dosage requirements [1].

Historically, peptide and protein pharmaceuticals have been delivered by paranteral administration because they are neutralized after oral intake due to their sensitivity to acidic conditions and enzymatic digestion. Some of these peptides can be given by transdermal and nasal delivery systems. However, it is still a challenge to deliver proteins and peptides orally into the systemic circulation. The drawback such as poor absorption due to bulky size and high hydrophilicity prevent designing oral dosage forms. Chemical modification of the polypeptide can increase absorption and render it less instable and perhaps increase its lipophilicity [2]. However, it is not possible to modify the structure of several peptides whose activities are dependent on tertiary structure and steric confirmation. Although the cyclic polypeptide such as cyclosporine, found to be well absorbed from the GI tract. Several attempts made to improve their bio-availability following oral administration failed due to lack of established, scientific concepts. Colloidal delivery systems like liposomes, microsphere, or emulsion system can protect peptides and proteins from the harsh condition of the GI tract. Addition of surfactant could greatly increase the membrane permeability however; clinical studies have not confirmed these concepts [3]. The major biological barrier to the oral delivery of peptide-based drugs includes the intestinal lumen, intestinal mucosa, and biochemical barrier. This review will focus on the formulation strategies used to enhance oral bioavailability of peptide based drugs. The drug polymer conjugate created provides molecular stability, transcellular transport and better pharmacokinetics. Depending on the pharmacodynamics of the peptides, various oral mucosal delivery systems can be designed. However, the physico-chemical and biological properties of these agents impose limitations in formulation, and development of optimum drug delivery systems as well as on the route of delivery.

1.1. Oral Cavity

Over a decade, there has been a particular interest in delivering drugs, especially peptides and proteins via the buccal route. Buccal mucosa is highly vascularised and high blood supply in reticulate vein enhances the absorption in this route. Peptide absorption occurs across oral mucosa by passive diffusion and it is unlikely that there is a carrier mediated transport mechanism [4], which provides direct entry into the systemic circulation thus avoiding first pass effect and degradation in GIT. Lozenges and sublingual tablets have been used for several decades. Based on the buccal absorption test by Beckett and Triggs [5], it was found that the buccal absorption of drugs is significantly correlated with their pH dependent renal excretion and protein binding [6]. Studies have shown that the rate of drug appearance in the systemic circulation through the buccal mucosa is slower than the rate of drug

disappearance from the buccal cavity [7]. These findings have confirmed by others for meperidine [8], morphine [9-10] and Insulin [11-13].

Other than the low flux associated with buccal mucosal delivery, a major limitation of the buccal route of administration is the lack of dosage form retention at the site of absorption. However, adhesive dosage forms such as gels, films, tablets and patches can overcome these limitations. They can localize the formulation and improve the contact with the mucosal surface to improve absorption of peptides and proteins [14].

Chitosan, a mucopolysaccharide, has been claimed to act both as a bioadhessive and permeabilizer. Permeability enhancement effect of chitosan in gel form for oral mucosa was investigated with transforming growth factor – beta (TGF-beta). Permeability was determined by measuring the flux of TGF-beta across porcine oral mucosa in an in vitro system. The enhancing effect of chitosan on buccal permeation of hydrocortisone and transforming growth factor beta (TGF-) has been reported [15].

A gold nanoparticle with chitosan has been investigated for delivery of Insulin through mucosal layer. Gold concentration in the plasma determined by inducting coupled plasma measurements. The *in vivo* studies revealed that increased pharmacodynamic activity and control of elevated glucose level [16]. It has been shown that buccal penetration can be improved by using various classes of transmucosal and transdermal penetration enhancers such as bile salts, surfactants, and fatty acids and their derivatives, chelators, cyclodextrin and chitosan. Among these chemicals used for drug permeation enhancement, bile salts are most common. Flat faced core tablet containing 12 or 32mg of hakea (mucoadhesive component) and 40mcg (200 IU) of Salmon calcitonin (sCT) per tablet was formulated by direct compression. Serum calcium concentration indicated that sCT was delivered across the rabbit buccal mucosa [17]. Buccal tablet of Insulin with locust bean gum was prepared by direct compression method. It was evaluated for bioadhesion study, In vitro drug release, drug permeation and in vivo study. Polyethylen glycol and dimethyl ether 500 are used as permeation enhancer. Results found that promising and suitable candidate for buccal Insulin delivery [18]. Protein binding, oral delivery of these therapeutic drugs enhances the value of these agents to impart its pharmacological active in an effective manner to the target site.

1.2. Intestinal delivery

The normal structure and function of the GI epithelium are generated, by the action of over 20 different peptide and small molecular weight (MW) proteins such as transforming growth factors, trefoil peptides epidermal growth factor, and pancreatic secretary trypsin inhibitor [19]. Advances in biotechnology have lead to the availability of some synthetic and recombinant forms of peptides and proteins. However, the stress conditions in the GIT, such as the low pH in the stomach and the proteolytic activities in both the stomach and the small intestine, may lead to this early and irreversible inactivation [20].

In general, poor absorption of peptides across mucosal surfaces is caused by the high polarity and high molecular weight of this class of compounds and their susceptibility to proteolytic degradation both by brush border and cytosolic enzymes. Intestinal peptide absorption is further more reduced by the hostile environment of the gastro-intestinal tract i.e. the strong pH extremes and the abundant presence of very potent luminal enzyme systems [21]. On the other hand, peptide absorption in the duodenal intestinal part may show some advantageous features due to the minor brush border and cytosolic enzyme activity in comparison to the jejunal and ileal parts, and due to the large surface area of the upper intestine part for rapid peptide absorption in comparison to the colon [22-23]. Different drug carrier systems have been studied to deliver the peptide pharmaceuticals per-orally like Mucoadhesive polymers, Polymeric nanoparticles, Microspheres, Liposomes etc.

1.2.2. Nanoparticles

The concept of solid nanoparticles was proposed and pioneered by Speiser and coworkers. Polymeric nanoparticles (NP 10-1000nm) allow encapsulation of the drugs inside a polymeric matrix protecting them against enzymatic and hydrolytic degradation. One limitation of NP as oral delivery system is the requirement that particles need to be absorbed from the gastrointestinal tract at a sufficient rate and extent. The strategy to overcome gastrointestinal barrier is the association of drug with a synthetic colloidal carrier system. This concept provides improved drug stability against enzymatic degradation in the harsh intestinal environment due to the protection offered by polymer matrix [24]. Various colloidal carrier systems have been studied for absorption enhancement of peptides, such as sub-micron emulsion, lipid suspensions, liposomes [25], polymeric nano-microparticles [26-27]

Oral administration of Insulin is beneficial due to its direct delivery to liver. The permeation of Insulin across epithelium is very slow due to its high molecular weight and very rapidly degraded by enzyme. These problems can be solved by changing the physicochemical properties of Insulin, using effective carrier system and cross linking with macromolecules [28]. The Insulin nanoparticles were prepared by complex coacervation method (Prusty et al.) It has been evaluated for entrapment efficiency, particle size, *in vitro*, *in vivo* studies, pharmacokinetic and biochemical parameters. It was found that significant reduction of serum glucose level and sustained for longer period of time [29].

The use of enzyme inhibitors is one of the ways to improve oral delivery of Insulin. Ovomucoids are enzyme inhibitor isolated from egg white of avian species. These ovomucoids were evaluated for their protection against trypsin and α-chymotrypsin mediated degradation of Insulin. DkOVM offered 100% protection against α-chymotrypsin and trypsin mediated degradation of insulin for 1 h at an enzyme inhibitor [30]. The concept of releasing enzyme inhibitor in controlled manner along with protein may enhance the stability of protein [31]. A serine protease inhibitor, serpin, can form covalent complexes with protease and thus protect from peptidase attack, the potential of aprotinin and soybean trypsin inhibitors, camostate mesilate and chromostatin enzyme inhibitors. Proteolytic degradation of human calcitonin and insulin in poly isobutyl cyanoacrylate nanocapsules was slower than the free peptides' The current hypothesis to explain the uptake of small amounts of particles is that there is a selective absorption via M cells especially in Payer's patches. Particles that dissolve above a given pH value are potentially interesting for releasing the peptides at a specific site of the GItract. Watnasirichaikul et al prepared and evaluated PBLA (poly isobutyl cynoacrylate) nanocapsules in w/o micro emulsion by interfacial polymerization. It was found that the pH impact on release of insulin from PBLA nanocapsule. Slow release in acidic pH and increased release in neutral pH [32].

Table-1
Approaches used in oral Protein formulation [34]

Approaches	Systems	Outcomes for absorption	Drawbacks
Absorption enhancers	Bile salts, fatty acids, surfactants, salicylates, chelators, zonular occludens toxin	Increase membrane permeation	Available transport of both protein/peptide drugs and undesirable molecules present in GIT
Enzyme inhibitors	Sodium glycocholate, camostat mesilate, bacitracin, soybean trypsin inhibitor, aprotinin, CkOVM, DkOVM, polymer-inhibitor conjugates	Resist enzyme degradation present in stomach and intestine	Available inducing severe side effects in chronic therapy
Mucoadhesive polymers	P(MAA-g-EG) hydrogel microparticles, lectin-conjugated alginate microparticles, thiolated polymers	Site-specific delivery and improve membrane permeation	Limitation due to the natural mucus turnover in intestine
	Gastrointestinal mucoadhesive patch system Mucoadhesive polymer–inhibitor conjugates	Site-specific drug delivery and resist enzyme degradation	Limitation due to the extensive costs of certain enzyme inhibitors
Formulation vehicles	Emulsions –S/O/W emulsion –O/W emulsion –Enteric-coated O/W emulsion	Protect drug from acid and luminal proteases in the GIT and enhance permeation through intestinal mucosa	Physicochemical instability in long-term storage and requirement for storage at low temperatures
	Liposomes –Double liposomes –Fusogenic liposomes –Crosslinked liposomes	Improve physical stability and increase membrane permeation	Low stability of liposomes
	Microspheres –Eudragit S100 microspheres –pH-sensitive P(MAA-g-EG) microspheres	Prevent proteolytic degradation in stomach and upper portion of small intestine. Restrict release of drug to favorable area of GIT	Concerns of protein stability during processing, release and storage
	Nanoparticles –PMAA/chitosan/PEG nanoparticles –Polystyrene/chitosan/PLA–PEG nanoparticles	Prevent enzymatic degradation and increase intestinal epithelial absorption	Low loading efficiency of hydrophilic drugs, difficulty of precise size control and avoidance of particle aggregation

Abbreviations; CkOVM, chicken ovomucoid; DkOVM, duck ovomucoid; S/O/W, solid-in-oil-in-water; P(MAA-g-EG), poly(methacrylic acid-g-ethylene glycol); PEG, Poly(ethylene glycol); PLA, poly(lactic acid); GIT, gastrointestinal tract.

Furthermore prolonged contact of NP with absorptive gastrointestinal cells may be achieved using bioadhesive polymer. Graft copolymers like poly (N-isopropylacry lamide) with polystyrene was used to prepare nanoparticles incorporated with Salmon calcitonin (sCT). The system demonstrated enhanced absorption by mucoadhesion and increased stability against digestive enzymes [35].

1.2.3. Microspheres

Polymer microspheres can also be used to deliver proteins. Micro particles made of bioerodible polymers offer the possibility of creating tailor-made system for controlled release. Double emulsion technique can be used to prepare microcapsules and size of capsules can be altered based on the viscosity of the solution and on the velocity of the mixing processes. Additives like PEG 6000 reduce the encapsulation of a model peptide whereas sodium sulfate increased the encapsulation efficiency. The pH of the organic phase has an important impact on the encapsulation. The influences of pH, polarity and viscosity of the surfactant phase on encapsulation still have to be determined. Small thermoplastic microspheres delivered orally are able to cross the intestinal epithelium; either through the Payers patches [36] and/or the regular absorptive epithelium. Three major mechanisms for improving oral delivery of proteins first by the spheres can protect proteins from proteolysis, second the spheres cross the intestinal mucosa and third the microsphere change the inter tissular distribution of the protein throughout the organism.

The regional variation in uptake of Proteins and Peptide in GIT was observed. The site specificity of peptide absorption in GI tract may be depends on uptake mechanism. The emulsion dosage form containing cyclosporine absorbed from the small intestine. It was found that cyclosporine in PEG solution absorbed more in the duodenum. The dipeptides angiotensin–converting enzyme (ACE) inhibitor uptake in upper small intestine, whereas elanapril a modified dipeptide ACE inhibitor absorption in jejunum. The proteolytic activity in ileum is extensive this may be the reason for higher jejuanl absorption of peptide [37]. In a specific study, the administration of 100 IU/kg of insulin in 250-300nm isobutyl 2-cyanoacrylate microspheres directly into the duodenum, jejunum, ileum and colon led to reduction in serum glucose levels. The greatest blood glucose reductions of 65% was seen in the ileum while a 50% reduction was seen in the duodenum, and jejunum and a 30% reduction was seen in the colon[38]. In an earlier study, a similar oral insulin formulation of 25 IU/kg insulin in isobutyl 2-cyanoacrylate microspheres produced 50% reduction in fasted serum glucose levels in streptozotocin induced diabetic rats as compared to 60% reduction in rats given the same dose subcutaneously [39]. pH sensitive micro-particles can be prepared using derivatised amino acids [40]. Benzoylated and phenyl sulfonylated single amino acids are novel, low molecular weight, and self-assembling in nature. At low pH, these molecules aggregate to form microspheres that will dissolve itself readily under neutral conditions. With this technique, entrapment of nearly 60% dissolved peptides can be achieved. Morishita et al [41] investigated the possibility of preparing pH sensitive particles that would dissolve in the jejunum or the ileum. To enhance the potentials of these particles, protease inhibitor (aprotinin) was used. The mucoadhesive polymer, polycarbophill, can virtually able to improve the intestinal absorption of 9-desglycinamide-8-arginine vasopressin (DGAVP). A controlled release bioadhesive drug delivery system, consisting of microspheres of poly (2-hydroxyethyl methacrylate) with a mucoadhesive polycarbophil-coating, as well as fast release formulation consisting of an aqueous solution of the peptide in a suspension of polycarbophil particle was tested for its effect [42]. The effect appeared to be dose-dependent, indication of intrinsic penetration enhancing properties of the mucoadhesive polymer. A prolongation of the absorption phase in vitro in the chronically isolated loop in-situ suggested that the polymer was able to protect the peptide from proteolytic degradation.

1.2.4. Liposome

The potential usefulness of liposomes as drug carriers has attracted considerable interest [43]. The drugs encapsulated in liposomes are sufficiently protected from enzymatic attack and immune recognition. Various attempts have been made to apply liposomes to the preparation of oral insulin [44]. Phospholipid vesicles are capable of encapsulating both hydrophobic and hydrophilic drugs they are biodegradable and are non-toxic. Dipalmitoyl phosphatidyl choline and dipalmitoyl phosphotidyl ethanol are studied for their resistance to pancreatic phospholipase A2 catalyzed hydrolysis. The entrapment of insulin increased with a rise of proportion of negatively charged phosphatidyl ethanol in the mixture [45]. Polymerized liposomes developed by Langer et al., Protein drug was incorporated into hydrophilic and hydrophobic layers of the liposomes during polymerization. The polymerized liposomes improved the stability against the harsh conditions of GI tract but cannot increase the

permeability of the protein drugs through the epithelial layer of GI tract [46-47]. The lipid composition and physical state of liposomes are important determinants of therapeutic effect. As the acetated tryptic digest insulin made by negatively charged liposome containing phosphatidyl inositol, which enter the blood stream, and will be competitive in receptor binding with hormone molecules [48].

1.3 Colonic delivery of peptides and proteins

Colonic drug delivery is a relatively new scientific area that has been developed during the last 10 to 15 years. The experience gained during this period is of great importance for the development of targeted delivery system with reliable drug release property. A reliable colon drug delivery could also be an important stern position for the colonic absorption of peroraly administered undigested; unchanged and biologically active peptide drugs [49]. Since the large intestine is relatively, free of peptidases [50]. Novel azopolymer coated pellets containing insulin was developed by Tozaki et al [51]. The intestinal absorption of insulin and eel calcitonin [Asu (1, 7)] after oral administration was evaluated by measuring the hypoglycemic and hypocalcemic effects. The findings suggest that azopolymer coated pellets may be useful for colon specific delivery of proteins including insulin and Asueel calcitonin. The extremely large variation in glucose levels after administration of insulin with azo polymer coated capsule to beagle dogs could also be explained in terms of difference in GI transit and microbial degradation in different dogs [52]. To rationalize partially the differences encountered in microbial degradation of azo polymers, [53] tested for the influence of polymer hydrophilicity. However, a balance between the hydrophobic and hydrophilic constituents of the polymer is important in optimizing the system. Incorporation of methacrylic acid in the polymer backbone yielded water insoluble polymers with a pH dependent degree of swelling. But the polymers with the highest degree of swelling in the colonic environment are degraded faster [54]. Depending on the nature of the polymer, the azo reduction can result in complete chain cleavage (formation of amines) or can stop at the intermediate stage (hydrazoformation).

CODESTM is developed as a colon-specific drug delivery system. The core tablet coated with three different polymeric layers containing insulin, lactulose, meglumine, polyethylene oxide, citric acid, and sodium glycocholate. Thus lactulose is used to protect the system through stomach and intestine and degraded to release drug in the colon. Meglumine and citric acid are pH adjuster and an insulin solubilizer, respectively, whereas sodium glycocholate is used as an absorption enhancer. Their combination with polyethylene oxide in the tablet core promotes a gel barrier that allows a sustained release of insulin in the colon of dogs [55-56].

FUTURE PROSPECTS

During the last decade, various delivery system based on variety of strategies have been investigated for oral delivery of peptides and proteins. Although different site-specific delivery systems have been developed for delivering bioactive peptides and proteins each has got its own limits to deliver the drug. There is a substantial difficulty in targeting of peptides and proteins using currently available approaches. The prepared oral site-specific delivery systems are those, which rely on conditions encountered in the GIT, since these systems will give true site-specific delivery.

Table-2 Oral delivery of peptides [57]

Company	Details	Technology	Claims	Phase
Access	Oral, receptor-mediated uptake	CobOral	Insulin, hGH	Preclinical
Aegis	Buccal, oral	Intravail	AFPep, Octreotide	Preclinical
ArisGen	Buccal, oral	Ariscrown	Exendin, hPTH, Insulin	Preclinical
Biodel	Sublingual film tablet	VIAtab	Insulin	Phase I
Proxima Concepts	Oral, enteric coated capsule	Axcess™	Calcitonin, hPTH	Phase II
Chiasma	Oral, oily suspension of enhancers	TPE Technology	Octreotide	Phase III
Emisphere	Oral Pasive trancellular uptake	Eligen	Calcitonin, Insulin, GLP-1, PYY	PI – PIII
Merrion	Oral enteric coated tablet	GIPET	Insulin, GLP-1, GnRH Analog	PI
Midatech/Monosol	Buccal film, nanoparticles	PharmFilm	Insulin	PI
NanoMega Medical	Oral, Nanoparticles		Insulin	Pre
NOD Pharmaceuticals	Oral, nanoparticles	NOD	Insulin	PI
Oramed	Oral, enteric coated tablet		Insulin, Exentatide	PII
Unigene	Oral, enteric coated tablet	Peptelligence	Calcitonin, hPTH, CR845	PII-PIII

Pharmaceutical approaches such as mucoadhesive patch/tablet, coating with pH sensitive polymer, biodegradable polymer, and preparing biodegradable nanoparticles and hydrogels are currently being evaluated for oral delivery of peptides and proteins. Recently a new design of delivery system is undergoing phase II clinical studies i.e. gastrointestinal mucoadhesive patch system (GI-MAPS). To overcome the poor membrane permeability of peptides and proteins, many scientists have been studying the use of absorption enhancers, enzyme inhibitors and enteric-coated formulation in improving the bioavailability of peptides and proteins [58].

CONCLUSION

In conclusion, drug delivery through oral route is challenging. The bioavailability of drugs remains to be an active area of research. Several sites in the GIT have been exploited but there are no major breakthrough with broad estimated by researchers, by studies reviewed herein indicates that several peptides and proteins can be administered orally for systemic delivery. Several strategies are currently being used to introduce them into the specific site of GIT and use of absorption enhancers, enzyme inhibitors and muco-adhesives should improve the oral bioavailability of peptides and proteins.

Reference:

1. Soyani, A. P.; Chein, Y W. Systemic delivery of peptides and protein across absorptive mucosa. Crit. Rev. Therap. Drug. Carrier. Syst., 1996, 13, 85-184.
2. Keld Fosgerau and Torsten Hoffmann. Peptide therapeutics: current status and future directions, Drug Discovery Today; 2015, Vol.20 No.1.
3. B.J. Aungst. Intestinal permeation enhancers. J Pharm Sci. 2000 Apr;89(4):429-42.
4. Gardner, M. G., Intestinal assimilation of intact peptide and protein from diet: a neglected field. 1986, 9, 289-331.
5. Beckett, A. H., and Triggs, E. J., Buccal absorption of basic drugs and its application as an invivo model for passive transfer through lipid membranes. J. Pharm. Pharmacol. 1969, 19, 315-415.
6. Randhawa MA, Turner P. Buccal absorption of drugs: an in vivo measurement of their innate lipophilicity, Int J Clin Pharmacol Res. 1988;8(1):1-4
7. Jeremy A. Bartlett and Kees van der Voort Maarschalk; Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine, AAPS PharmSciTech. 2012 Dec; 13(4): 1110-1115.
8. Ritschel WA, Neub M, Denson DD. Meperidine pharmacokinetics following intravenous, peroral and buccal administration in beagle dogs. Methods Find Exp Clin Pharmacol. 1987 Dec;9(12):811-5.
9. Beyssac E, Touaref F, Meyer M, Jacob L, Sandouk P, Aiache JM. Bioavailability of morphine after administration of a new bioadhesive buccal tablet. Biopharm Drug Dispos. 1998 Sep;19(6):401-5.
10. Lona Louring Christrup, Christian Broen Christensen, Gitte Juel Friis, Aksel Jorgensen Improvement of buccal delivery of morphine using the prodrug approach, International Journal of Pharmaceutics, Volume 154, Issue 2, 26 August 1997, Pages 157-165.
11. Aungst, B.J, Rogers, N.J., and Shefter E. Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter, The J. Pharmacol. Exp. Ther., 1988; 244:23-27.
12. Aungst, B.J. and Rogers, N.J., Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery, Int. J. Pharm., 1989;53:227-235.
13. Ishida M, Machida Y, Nambu N, and Nagai T, New mucosal dosage form of insulin, Chem. Pharm. Bull., 1981; 29:810-816.
14. Pauleti, G. M.; Gangwar, S.; Knipp, G. T.; Nerurkar, M. M., Okumu, F. W., Tamura, K., Siahann, T. J., Borchardt, R. T., Structural requirement for intestinal absorption of peptide drug. J. Con. Rel. 1996, 41, 3-17.
15. Senel S, Kremer MJ, Ka? S, Wertz PW, Hincal AA, Squier CA. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa Biomaterials. 2000 Oct;21(20):2067-71.
16. D.R.Bhumka, B.M. Joshi, M.Sastry and C.B. Pokharakar; Chitosan reduced gold nanoparticle as novel carrier for transmucosal delivery of Insulin, Pharmaceutical Research; 2007, Vol 24 No 8 P 1415-1426.
17. Alur H H, Beal J D, Pathers I, Mitra A K, Johnston T P. Evaluation of novel, natural oligosaccharide gum as a sustained release and mucoadhesive of calcitonin buccal tablet, J.Pharm. Sci, 1999, Dec 88(12) 11313-11319.
18. B. Prasanth, V. Sankaranand, V. Venugopal; Formulation and evaluation of bucco adhesive tablets of Insulin, International Journal of Research in Pharmacy and Chemistry, 2011, Vol.1 172-178.
19. Gruber, P.; Longer, M. A.; Robinson, J. Some biological issues in oral controlled drug delivery. Adv. Drug. Del. Rev. 1987, 1, 1-18.
20. Phillips, S. T. Transit across the ileocolonic junction In: Drug delivery to the gastrointestinal tract. Hardy J. G., Davis, S. S., Wilson. C. G., Ed,: Ellis Horwood Chichester, 1989; 63-74.
21. Burton, P. S., Conradi, R. A., Ho, N. F. H., Hilgers, A. R., Borchardt, R. T., How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 1996, 85, 1336-1340.
22. Fell, J. T., Targeting of drugs and delivery systems to specific site in the gastro intestinal tract. J. Anat. 1996, 189, 517-519.
23. Phillips, S. F., Gastrointestinal physiology and its relevance to targeted drug delivery. Capsugel Symposia Series (Capsugel, Arlehecin Switzerland) 1993; 9-18.
24. Damge, C., Michel, C., Apprahamian, M., Couvreur, P., Devissaguet, J. P., Advantage of a new colloidal drug delivery system on the insulin treatment of streptozotocin induced diabetic rats. Diabetologia 1986, 29, 531.
25. Ritschel, W. A., Targeting in the gastro intestinal tract: New approaches, Meth. Find. Exp. Clin. Pharmacol. 1991, 13(5), 313-336.
26. Vranckx, H., Demoustier, M., Deleers, M., A new nanocapsule formulation with hydrophilic core: application to the oral administration of salmon calcitonin. Eur. J. Pharm. Biopharm. 1996, 42, 345-347.
27. Allenman, E., Guray, R., Doekker, E, Drug loaded nanoparticle preparation method and drug targeting issues. Eur. J. Pharm. Biopharm. 1993, 39, 173-199.
28. Arun Verma, Nitin Kumar, Rishaba Malviya and Promod Kumar Sharma. Emerging Trends in Non invasive Insulin Delivery; Journal of Pharmaceutics, Volume 2014 Article ID 378048 9Pages.
29. A. K. Prusty and S. K. Sahu, "Development and evaluation of insulin incorporated nanoparticles for oral administration." ISRN Nanotechnology, Vol.2013, Article ID 591751, pp6, 2013.
30. V.Agarwal, I.K.Reddy and M.A Khan, Oral Delivery of Proteins: Effect of Chicken and Duck Ovomucoid on the Stability of Insulin in the Presence of ?-Chymotrpsin and Trypsin, Pharm. Pharmacol. Commun. (2000), 6, 223-227.
31. Vikar Agarwal and Mansoor A Khan; Current status of the oral delivery of Insulin . Pharmaceutical Technology oct 2001.
32. Watnasirichaikul S, Rades T, Tucker I G, Davis N M; In vitro release and oral bioactivity of Insulin in diabetic rats using nanocapsules disperesed in Biocompatible microemulsion, J.Pharm Pharmacol 2002: 54(4); 473-480.
33. Keyongsoon Park, Ick Chan Kwon, Kinam Park, Oral protein delivery: Current status and future prospect, Reactive & Functional Polymers 71, (2011) 280-287.
34. JMBR: A Peer review journal of Biomedical Sciences, June 2004, Vol3, No 1 pp 7-20.
35. Pappo, J., Ermack, T. H., Uptake and translocation of fluorescent latex particles by rabbit Payer's patch follicle epithelium: a quantitation model for M. cell uptake. Clin. Exp. Immuno,. 1989, 76, 144-148.

36. Dougherty, A. L., Mrsny, R. J., Regulation of the Intestinal epithelial paracellular barrier. Pharm. Scio. Techno. Today. 1999, 2, 281-287.

37. Ram I. Mahato, Ajit S. Narang, Laura Thoma, & Duane D. Miller; Emerging trends in oral delivery os Peptide and protein drugs; Critical Reviews in therapeutic Drug Carrier System, 2003, 20 (2&3); 153-214.

38. Andrinov, A. K., Payne, L. G., Polymeric carrier for oral uptake of microparticulates. Adv. Drug. Dev. Rev. 1998, 34, 321-338.

39. Damge, C., Michel, C., Apprahamian, M., Couvreur, P., Devissaguet, J. P., Advantage of a new colloidal drug delivery system on the insulin treatment of streptozotocin induced diabetic rats. Diabetologia 1986, 29, 531

40. Leon bay, A., McInner, C. M., Wang, N., Demori, F., Achan, D., Lercara, C., Sarubbi, D., Haos, S., Press, J., Barentesvich, E., Broin, B. D., Milsten, S., Paton, D., Microspheres formation in a series of derivatized alpha amino acids preparation molecular modeling and oral delivery of salmon calcitonin. J. Med. Chem. 1995, 38, 4257-4262.

41. Morishita, I, Morishita, M., Takayama, K., Machida, Y., Nagai, T., Enteral insulin delivery buy microsphere in 3 different formulation using Eudragit L100 and S100. Int. J. Pharm. 1993, 9, 29-37.

42. Leussen, H. L., Verhoef, J. C., Borchardt, G., Lehr, C. M., DeBoer, A. G., Junginger, H. E., Mucoadhesive polymers in peroral peptide drug delivery II carbomer and polycarbophill are potent inhibitor of the intestinal proteolytic enzyme trypsin. Pharm. Res. 1995, 12(9), 1293-1298.

43. Deshmukh, D. S., Bear, W. D., Brockerhoff, H., Can intact liposomes be absorbed in the gut? Life Sci. 1981, 28, 239-242.

44. Spangler, R. S., Insulin administration via liposomes. Diabetes. Care 1990, 13, 911-922.

45. Kisel, M. A., Kulik, L. N., Tsyborsky, I. S., Vlasov, A. P., Vorob'you, M. S., Kholodova, E. A., Zabarovskauya, Z. V., Liposomes with phosphatidyl ethanol as a carrier for oral delivery of insulin: studies in the rat. Int. J. Pharm. 2001, 216, 105-114.

46. R.Langer, NatureNature 392 (1998) 5-10.

47. J.Okada, S. Cohen, R. Langer, Oral delivery of vaccines using polymerized liposomes. In US patent 5762.904 (1998).

48. Kato, Y., Hosokawa, T., Hayakawa, E., Ito, K., Influence of liposomes on tryptic digestion of insulin. Biol. Pharm. Bull. 1993, 16, 457-461.

49. Borcharkt, R. T., Nayer, N. H., Rything, J. H., Shek, E., Touitou, E., Higuchi, W. I., The delivery of peptide. J. Pharm. Sci. 1989, 18, 883-892.

50. Keligo, D. J., Hamilton, J. P., Quantitative determination of macromolecular transport rate across intestinal Payer's patches. Am. J. Physiol. 1983, 244, G637.

51. Tozaki, M., Nishiuka, J., Komoike, J., Okada, N., Fujita, T., Muranishi, S., Kim, S. J., Terashima, H., Yamamoto, A., Enhanced absorption of insulin and (Asu 1-7) eel calcitonin using novel azo polymers coated pellets for colon specific drug delivery. J. Pharm. Sci. 2001, 90, 89-97.

52. Saffran, M., Field, J. B., Pena, J., Jones, R. H., Oleuda, Y., Oral insulin in diabetic dogs. J. Endocrinol. 1986, 131, 267-278.

53. Cheng, C. L., Gehrke, S. H., Ritschel, W. A., Development of an azopolymer based colonic release capsule for delivering protein/macromolecules. Meth. Find. Exp. Clin. Pharmacol. 1994, 16. 271-278.

54. Vanden mooter, G. Samyn, C., Kiget, R., The relation between swelling property and enzymatic degradation of azo polymer designed for colon specific drug delivery. Pharm. Res. 1994, 11, 1737-1741.

55. Li J, Yang L, Ferguson SM, Hudson TJ, Watanabe S, Katsuma M, Fix JA. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES) in multi-pH media using United States Pharmacopeia apparatus II and III. AAPS PharmSciTech. 2002;3(4):E33.

56. Katsuma M, Watanabe S, Kawai H, Takemura S, Sako K. Effects of absorption promoters on insulin absorption through colon-targeted delivery. Int J Pharm. 2006;307(2):156-62.

57. R. Lax, C. Meenan; Challenges for Therapeutic Peptides Part 2: Delivery Systems Innovations in Pharmaceutical Technology / Issue 43, Dec 2012, P42-45.

58. Eiamtrakan S, Itoh Y, Kishimoto J, Yoshikawa Y, Shibata N, Murakami M, Takada K, Gastrointestinal mucoadhesive patch system (GI-MAPS) for oral administration of G-CSF, a model protein, Biometerials; 2002, Jan; 23(1): 145-152.

Fostering Pharmaceutical Excellence

Swarnlata Saraf
Anshita Gupta
University institute of Pharmacy,
Raipur, Chhattisgarh

Macrophage Migration Inhibitory factor (MIF) an important link in UVR induced carcinoma

Introduction:

Macrophage Migration inhibitory factor (MIF) are important link in UVR induced carcinoma. Exposure of ultraviolet (UV) radiation are the most significant reason of skin cancer. Ultra Violet radiations exposure causes damage to skin which are impermeable to reverse the activity. UV radiations triggers chain of reaction on intracellular level causing release of many cytokines like interleukin (IL)-1 , IL-6 , tumor necrosis factor (TNF-) and macrophage migration inhibitory factor (MIF) which leads to photoaging , immune suppression and finally carcinogenesis of skin.

The most common target for UV radiation is epidermal cells which receives excess of UV radiations. UV radiation consists of three chief rays viz UV A,UV B and UV C out of which UVA and UVB are the dangerous radiations which penetrate inside the skin membrane. Keratinocytes are the cells which are responsible for releasing biologically active cytokines in response to UV exposure. These cytokines directly or indirectly affects various cells like endothelial cells, dermal cell, dermal fibroblast etc. which triggers the release of adhesion molecules including ICAM-1 ,VCAM-1 , E-selection etc causing sunburn cells. The overall action is manifestated in turns of inflammation , redness and itching.
Macrophage migration inhibitory factor:

These are a pleiotropic inflammatory mediator which was primary considered as cytokine responsible for concentrating macrophages at the site of inflammation. They are also called as strcker for micro macrophage activation and are crucially involved in cell mediated immunity. Chemically MIF consist of 114 amino acids and has a tertiary structure. Macrophage inhibitory factors have been considered to play important role in varieties of skin disorders.

Macrophage inhibitory factors participate in the degradation of dermal cell and collagens by stimulating MMP-1 in skin photoaging. Similarly, MIF has also proven its expression in the pathogenesis & progress of non-melanoma skin cancer (NMSC). On acute exposure of UVB radiations an increase in MIF occurs which causes cessation of p-53 dependent apoptosis and inducing skin cancer. The accumulation of MIF has also been proved in melanocyte cells when analysed histochemically. In malignant melanoma , an over expression of MIF has been observed.

MIF is also expressed in other skin diseases like:

- Allergic and Irritant contact dermatitis
- Atopic dermatitis
- Psoriasis
- Vitiligo
- Alopecia areata
- Lupus erythamatous
- Xeroderma Pigmentosum
- Gorlin's Syndrome



Figure 1: showing Effect of MIF

Macrophage Inhibitory factor (MIF) does not always acts as a criminal factor but also accelerate wound healing in tissue injury and regulates several phases of inflammation. MIF also acts as a valuable diagnostic test for diagnosis of drug eruptions.

MIF has been the subject of intensive recent researches. It has proven to play a critical role for this molecule in innate and adaptive immunity. MIF is expressed by a variety of cells including eosinophils, lymphocytes, macrophages, epithelial cells as well as endothelial cells. This protein shifts macrophages to inflammation loci and also activates lymphocytes, granulocytes and monocytes/macrophages. In the field of dermatology, MIF is believed to be a criminal agent in many diseases but, its contribution to other aspects of skin biology is currently unknown.

Considering that MIF has been manifested to be involved in the immunopathogenesis of cutaneous disorders; production of novel generations of the chemical or herbal preparations selective targeting of MIF, anti-MIF antibody and specific chemical MIF inhibitors can be the valuable therapeutic avenues in the future for the treatment of MIF-related dermatologic disorders. Moreover, according to the unique association between MIF and glucocorticoids, MIF antagonist agents can also highlight an impressive strategy for steroid-sparing therapies in patients with refractory autoimmune diseases. Utilization of antibody, soluble receptor or small molecule technologies may result in the capacity to test in the clinic the value of MIF in inflammatory diseases.

References:

1. Zhao X., Li H., Lee R.J. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv. 2008; 5(3):309-19.
2. Kukowska-Latallo J.F., Candido K.A., Cao Z., et al. Nanaoparticles targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65:5317-5324.
3. Lua Y., Segab E., Leamona CP. Et.al, Folate Receptor-Targeted Immunotherapy of Cancer Mechanism And Therapeutic Potential. Adv.Drug Deliv. Rev. 2004;56:1161- 1176
4. Gupta A., Kaur C.D., Jangdey M., Saraf Swarnlata; Matrix metalloproteinase enzymes and their naturally derived inhibitors: novel targets in photocarcinoma therapy. Ageing Res Rev. 2014 Jan;13:65-74. doi: 10.1016/j.arr.2013.12.001. Epub 2013 Dec 16
5. Deep Chanchal, Saraf Swarnlata; Novel approaches in herbal cosmetics; Journal of cosmetic dermatology, 2008, 7 (2), 89-95
6. Mukherjee SG, O'Claonadh N, Casey A, Chambers G. Comparative in vitro aVitro. 2012;26(2):238-51
7. Kaur M., Agarwal C, Singh R.P, et.al. Skin cancer chemopreventive agent, a-santalol, induces apoptotic death of human epidermoid carcinoma A431 cells via caspase activation together with dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis.2005;26(2):369-380
8. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Annals of the New York Academy of Sciences 2005;1056: 206-17.
9. N Verma, A Gupta, S Saraf, S Saraf; Potential of flavanoidal rich herbal formulation in treating skin aging complications;Journal of Atoms and Molecules;2015; 5 (2), 880.
10. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxidants & Redox Signaling 2008;10:511-45.

Utkala Mariganti
Manager, Telemedicine
Columbia Asia Hospital, Bangalore

Community Pharmacist- A Piece of the Healthcare Puzzle

Globally, universal access to healthcare is of a major concern and there is a large pool of experts working on this issue and researching possible solutions.

India is no different and with the large and growing population and poverty being the ground reality, the need to find better solutions and look at changes that our system needs to come with one that if effective and indigenous to our needs and challenges is imperative.

Allied health services play a crucial role in the effective delivery of healthcare and continuity of patient care. A knowledgeable and experienced community pharmacist is crucial piece of the healthcare puzzle. The key word here is knowledgeable and well trained. So far, pharmacists have been seen as a retail unit with less or no contribution to patient care. We can blame the system for this scenario or take some responsibility and critically analyze why despite innumerous pharmacy colleges in the country and advancement of technology, we have failed to break the barriers and enter the active aspects of patient care in our health care system.

The answer is rather simple. We have not been successful in gaining credibility among healthcare fraternity. Pharmacist licenses are still misused, the retail pharmacists or community pharmacists are not clear about their contribution to not only healthcare but society at large. Most likely, they have no passion or aptitude to be community pharmacists but are doing this because of their academic or professional limitations or financial need.

Before we get into the aspects of credibility, let's look at a few scenarios where a community pharmacist could be a part of continuity of care. A very common scenario is an elderly patient comes with a list of medicines he wants to purchase. Now, here we have a choice of just selling what he wants, or engage with him at multiple levels. How about asking if he would like the long term meds delivered home? How about asking him if he needs reminders for replenishing his insulins or such? Technology is a boon in this case. We should have a system where patient information is plugged in and date of purchase with dosage and other relevant information. The system should be able to generate the date when the refill is required and the pharmacist can call or sms the patient asking if he wants the refill to be done and sent home. This ensures that the patient is compliant with this treatment plan is not missing out on important medicines. A mechanism of keeping the prescribing doctor in loop could be implemented where the doctor knows how complaint his/her patient is on medications. Imagine how useful it would be for patients on insulins, anti hypertensives, even those pregnant women on folic acid etc.

Of course, imparting drug information is a major role of a pharmacist and that should be ingrained into every pharmacist. Giving out drug information saves the doctor's time, helps the patient understand the medicine better and precautions that he needs to take. A simple step of telling the patient what to expect could avoid panic situations like, "oh my god, my urine turned bright yellow, do I have a problem" when it is a well expected side effect with certain drugs.

When a pharmacist is accessible and approachable, in my experience people will acknowledge their contribution and will engage with the pharmacist better. Many people have questions about how to use glucometers, when to take certain medicines, drug interactions, alternatives. We can help patient make the right economic choice when they have financial problems yet need certain expensive drugs.

To be an effective pharmacist one needs to gain credibility and that can be done through:

1. Proper academic training
2. Internship at a hospital under supervision of doctors
3. Improving communication skills and networking skills
4. Reading and staying updated on new drug entrants into the market
5. A willingness to engage with doctors and patients
6. Most importantly, passion for patient care

When you become a competent pharmacist, you not only add value to the system on the whole but you also become a successful business as all these effect your bottom line. You have customer loyalty, you have the doctor's confidence and he will refer more patients to you, you increase your business through word of mouth for the wonderful services you are providing.

It is the right time for us all to look at the academic training of pharmacists, find gaps that need to be filled in creating better community pharmacists, liaison with hospitals for training, instill passion among students to take this field up voluntarily and desire to become good community pharmacists.

A Vijayshree Attri
Motivational Speaker &
Human Excellence trainer, Buoyancee
www.buoyancee.com

Lead yourself to Lead YOUR LIFE

How about a life without purpose?

Do you Really want toLIVE YOUR life or just live life?

If you truly want to live your life, then one's life should have a purpose, a goal which must define your destiny. If you are travelling your journey without destination then you are traveling actually nowhere.

Nothing has a meaning until we give one, if you really want to give meaning to your life then let's go thru to the 5 important steps which can decide the purpose of your life.

FIVE D's of GOAL Setting –

Direction
Edication
Determination
Discipline
Deadlines

1. **Direction -** if you want to see the rising sun , you must have to see towards east direction . You cannot see the rising sun by looking at west direction. similarly if you want to achieve something in your life you must decide it-

   "YOU MUST SET YOUR GOAL".

- **How to set your GOAL -** 1. Check your area of interest, 2.Check your scope of interest. Your area of interest will help you to define your goal & your scope of interest will tell you are in right direction of growth, do you have abundant scope in the "decided direction" for your Professional & Personal Growth.

2. **Dedication -** Once you decide your goal your dedication & efforts are required to full fill it.

   "You have to live your goal in reality to achieve it in reality"

- Plan your actions, collect all possible information & priorities your work.

  Take actions which will lead you more near to your goal.

3. **Determination -** Winners do not do great things they just have & live "winning attitude"

   Your determination towards your goal will decide your probability of success.

   "Once you finish the race then only it is declared as finished"

- Strong determination will help you to achieve your goal faster, for that you have to be focused on only those areas which will take you & your goal to the next level. You must have to maintain your "will power"

4. **Discipline -** Disciplined life is not about living with rules, it's about to maintain the consistency which will lead to a constructive result.

   "Reinforcement is the key to inculcate a habit in you "

- Successful people live successful habits stay honest & disciplined towards your goal.

  Only sufficient amount of sugar can make your tea sweet, similarly the amount of your hard work & consistency will define the rate your success

5. **Deadlines -** One must know, till when you want to achieve your goal.

   "You must finish one target to start a New one "

- Set your target, with a timeline to complete it. It will help you to set your next target towards your growth, and will also give you feeling of accomplishment &fulfillment.

Start living these 5 D's & you will certainly see that life is becoming easier, more organized & more meaningful towards success.

2016

EXPRESSIONS

CPPA@KCP

CPPA : Report on the Symposium

On 12th December 2015, CPPA, Krupanidhi College of Pharmacy had the rare privilige of hosting five luminaries from the industrial domain. Prakash Mallya was pivotal in bringing together such an assembly of speakers. The who's who of the pharma-healthcare industry delivered brilliant talks on diverse and cutting-edge topics such as: Indu Bhushan (CEO - Steer Pharmaceutical Development Centre, Bangalore) on Melt extrusion technology, Ajay Khopade (Senior VP - R&D, Sun Pharma Advanced Research & Discovery Centre, Baroda), on Nanotechnology in pharma and Novel drug delivery systems, Jitendra Kadam (Patent Landscape Analyst) on Intellectual property management, Dinesh Shenoy (Director - Pharma Research, Lupin Limited, Pune) on Barrier isolator technology - new generation sterile manufacturing, Sudhir Nayak (Head - Metabolics business unit, Biocon, Bangalore) on Recent trends in pharma marketing.

The Vice-Chairperson of Krupanidhi Educational Trust, Geetha Nagpal, graced the function. The teaching staff of KCP, Students of III B.Pharm, IV B.Pharm, I and II M.Pharm, Students and staff from Oxbridge College of Pharmacy and Dayanand Sagar College of Pharmacy, attended the symposium. Mallya and Principal, Raman Dang welcomed the guests with bouquets. Dinesh Shenoy introduced each guests before their seminar. At the end, a lively and interactive panel discussion was held and questions flowed from the audience to the panelists. Arshad compered the panel discussion.

The symposium gave the audience an opportunity to gain insight in diverse fields of the industry. Ajay Khopade gave an erudite seminar on Nanotechnology and its pharma application. He elucidated its wide ranging application, especially in the treatment of cancer. Dinesh Shenoy explained the cutting-edge technology of Barrier isolator systems. Jitendra Kadam gave a lucid presentattion on the patent regime. Sudhir Nayak gave an interesting seminar on recent trends in pharma marketing hiighlighting its importance in the current scenario. Indu Bhushan gave an excellent presentation on Melt extrusion technology and its varied applications.

Prabitha helped in the collection of attendance and feedback. Chandramouli delivered the vote of thanks. The Vice-Chairperson of Krupanidhi Educational Trust, Geetha Nagpal, presented mementos to the guest speakers.

The feedback for the symposium was extremely positive. They appreciated the variety of topics, organization of the seminar and the knowledge of the speakers. Following gives the transcript of the panel discussion.

Question for Dr. Ajay Khopade: How accuracte and specific will the nanotechnology products be while targeting tumour cells in case of cancer therapy?

Answer: Extremely good question. You are talking about black or white, yes or no type of effect. But still it is a grey area. Targeting is still at a lower level and upto 20% targeting can be achieved as of now. Upcoming antibody-based drug targeting may increase the level upto 60%. But if you are asking whether 100% is possible then that scenario is a little far ahead in the future.

Question for Dr. Ajay Khopade: Are there any specific health risks for nano products?

Answer: As far as the nanotechnologly products are concerned, which are by definition not below certain size levels, such products do not pose a serious health hazard. The examples which I have quoted are biophysical in nature, generally biocompatible and breakdown into biocompatible molecules. But the inorganic nano products, such as metallic nanoparticles, which go below 10 nm, may pose ceratin toxicity problems. But the question is valid and when you have a nano drug delivery system, a very different toxicological profile has to be explored.

Question for Dr. Ajay Khopade: What is the proof that nanotechnology anticancer products are better than regular chemotherapy?

Answer: When we look at cancer, it is a multi-factorial disease and very complex. When we try to develop nano products for cancer treatment we see how they will benefit the patient. For example, our product, paclitaxel nanoparticle is easy to formulate. But there are two problems with conventional drugs; one is severe hypersensitivity reaction for which doctors have to pre-treat the patient with a corticosteroid or antihistaminic drug. With nanotechnology product we don't have to give such a pre- treatment. Second thing is when you modify the drug and inject it into the body via infusion a number of scenarios are presented. In some kind of cancer patients, this offers a lot of benefits and in some other cases, this would be just partially beneficial. In metastatic breast cancer disease what we have found is that we are able to give more amount of drug via nanotechnology which increases the efficacy. The response rate of treatment is calculated by injecting the drug and after 21 days if the tumor has reduced by 30% then it is considered a positive response and the cycle is repeated and the response rate is measured at the end of each cycle. Our nano product was found to have 10% better response rate than conventional


Ajay Khopade

therapy. Also, grade 3 and grade 4 neuropathic conditions were reduced by less than half in the patients. So there is an incremental improvement in the quality of life of the patient and also in the efficacy of the treatment.

Question for Dr. Ajay Khopade: How can better stents be made for cardiac patients through nanotechnology?

Answer: Nanotechnology is being used to identify the plaques occuring in the heart caplillaries. They will be targeted to that particular region where there is a plaque. Thus nanotechnology / nanomaterials are improving the patient's life.

Question for Dr. Dinesh Shenoy: What are Pros and cons of O-RABs and C-RABS?

Answer: RABS basically means "Restricted Access Barrier Systems". So there is a restricted access.'O' means open and 'C' means closed. Both can be used for sterile manufacturing. But if it is a highly potent cytotoxic anti-cancer agent, C- RABS is more preferred as is it completely closed and sealed off. Human intervention in case of C-RABS is much lesser, so in short, C-RABS is one level short of isolator. The only difference is in terms of sanitisation; otherwise most of the conditions inside are the same.

Question for Dr. Jitendra Kadam: What about the patenting of nanotechnology products, is it going to get a fresh patent?

Answer by Dr. Jitendra Kadam: There are few biological products that cannot be patented. But in case there is a design/technology developed around it then that design/technology can be patented. If it has a new application then also it can be patented. The newer patent can be compared with the older patent and if there is novelty in design and application, patenting can be done.

Answer by Dr Ajay Khopade: In the case of our company, Paclitaxel molecule is off-patent and anybody can use that molecule. And we are making Paclitaxel solution by using a certain process A+B+C+ D+ E, which is different from what others have done. Hence, it becomes patentable. This patent will be evaluated by an examiner against all the prior arts and prior patents. If he finds it patentable, then only a patent will be given. That is what has happened in our case. Also the method of use for paclitaxel nano-formulation which we developed was novel as we were able to deliver 295mg/m^2 which was more than anybody else and was considered as new knowledge in giving the patent. Regarding cost I think there needs to be a balance. I think Mr. Sudhir from marketing will be able to give a better answer.

Answer by Mr. Sudhir Nayak: Cancer is mostly treated with cytotoxic drugs which are poisonous. It just a matter of how less of the poison can be given to treat the disease with lesser side effects. Abraxane was made by Celgene and Sun Pharma's nano- formulation improved upon it by delivering more dose of Paclitaxel. The earlier patent will remain with Celgene and for the new improvement, Sun Pharma got the patent. Now, coming to the cost, from innvovation point of view, it will be costly because a lot has been put in to create the new product and it needs to be safe also and clinical trials have to be performed. There will be a lot of marketing involved for this new product. But unlike foreign multinationals, Indian MNCs are sensitive to price and you will find them more competitive. In case of patent they may charge a little higher but in case of generics they are generous with the pricing. There are two reasons for it: one reason is the need to keep the price uniform with that of the competitor and second is that the developmental costs are much higher compared to outside India. So in layman's term, if you want power- steering option for your car, you would pay more because to develop power- steering, developmental costs are more.

Question for Shri. Indu Bhushan: If Indian drugs cost lesser than western drugs, is the quality same?

Answer by Shri.Indu Bhushan: The answer is not that simple. There are some myths and some truths; whatever bad name Indian industry has got in the last 20 years has less to do with quality and more to do with data integrity. For example, if my friend has come down from USA and he sees us not wearing helmets even though there is a law for it then it is a question of how much you are following the laws which are have been made. The question of quality is not that serious in case of Indian companies. Recall due to quality is very less. And Indian industry is known for generics, so I have not seen much difference in quality, there is absolutely no difference in quality. But the way we conduct our operations, then there our truthfulness is in question. Whether whatever was written was followed or not?It is there the data integrity is in question. To answer your concern about quality, for example, when someone gets approval for making a product it will be initially made as good as that available in the market. But after that is the quality of subsequent batches the same? That is the question. All pharma companies are under scrutiny in India, so much so that in injectables nobody is ready to set up a plant in India. They are scared. In democracy, everyone is naked and under scrutiny. Hence integrity is questioned. Quality can be assured in labs; but integrity cannot be tested in the lab. All the students should take note of this issue of data integrity for the future. People from US are saying that when I am seeing that there is a defect from 9000 miles, why in India a case is not filed against the culprit.

Answer by Prof. Mallya: Our Top 25 companies are fine with quality issues. The medicines of such top companies are available in US and Canada. But the lower strata of companies have issues with quality and such low strata companies don't even aspire to have markets internationally. So, that is an area of concern.


Jitendra Kadam

Question for Shri. Indu Bhushan: What are the career opportunities in Pharma?

Answer by Shri Indu Bhushan: Plenty! India is growing and we have a good future. And fortunately, unlike IT, Pharma is related to people's health directly. People want to live longer. There will be innovation in medicine. Today we are not doing much innovative research, we are more into generics. But there will be a change in perspective. Like Sun Pharma, slowly you will see more and more companies invest in innovative and fundamental research. I don't see any problems as far as Pharmacy profession is concerned. It is going to change and change is the way of life. Earlier therewere opportunities only in sales, marketing and manufacturing, then R&D processing and now it will be R&D with focus on fundamental and innovative research. IT companies like Google is investing in pharma and more will also join us.

Answer by Prof. Mallya: Just recently a top newspaper has reported that again Pharma is the sunshine industry.

Answer by Principal Dr. Raman Dang: Apart from conventional jobs there are opportunities like medical writing and outsourced jobs. Software companies are also requring pharma people for their inputs.


Prakash V Mallya

Question for Shri. Indu Bhushan: What are the emerging technologies that will revolutionize Pharma manufacturing industry? What about continuous manufacturing?

Answer: Pharma has not yet accepted continuous manufacturing as say, as Maggi is manufactured. Because of regulations and profitability they are not ready to change. But even aviation industry is regulated and profitability is even less than 1%. So if pharma is not ready to change it is due to protection of its profits. If they are sitting on a pile of profit why should they change? Until and unless competition comes and cuts your profits! India and China are trying to achieve innovation, because IP protection is less and due to their generics business. Most of the innovation is done by start-up and small companies. Then the bigger companies just acquire these companies. Today compared to earlier times, only 12 companies make 80% of pharma business, is it not a cartel? All other companies have changed, but pharma companies are protected and it is not changing that much. Monopoly is bad for innovation. How many people can afford 10,000 USD AIDS medicines? But India reduced it to 100 USD because of innovation as they wanted to take care of the suffering population.


Indu Bhushan

Question for Shri. Indu Bhushan: Is Hot Melt Extrusion (HME) suitable for sterile preparations?

Answer: Yes, it is. Infact HME is being used for making Ocuserts. Absolutely no problem, you can create a sterile environment, infact it is one of the advantages of HME and it is completely enclosed. HME is very amenable to sterile manufacturing.

Certificate Course in Regulatory Affairs

The certificate course in regulatory affairs was conducted in Krupanidhi College of Pharmacy form 30/01/2016-02/04/2016, as a joint endeavour of Greenchem Herbal Extracts and Formualtions and Krupanidhi College of Pharmacy for the benefit of students of I & II M.Pharm, V. Pharm D and IV B.Pharm. The staff of KCP also availed of this course. It was the brainchild of P.V. Mallya, Director, CPPA, who has tirelessly worked into making the endeavour successful. Through him, many technocrats and key people of the industries have come and delivered erudite seminars on various cutting-edge topics covering the vast, excting and employment-providing domain of regulatory affairs. Dr. Raman Dang, Principal, KCP has been an avid facilitator and supporter of this course ensuring smooth conduct of the course. Arshad Bashir Khan and Prabitha assisted P. V. Mallya in conducting the course.The Management of Krupanidhi educational trust must be lauded for promoting such courses which proved to be extremely advantageous to the students.

The inaugural course was held on 30/01/2016 and the speaker was P. V. Mallya, Director, CPPA. The topic was "Introduction to Global Regulatory Affairs". He delivered a scholarly seminar in which he covered the various regulatory agencies around the world such as FDA, MHRA, EMA, CDSCO, Health Canada and PMDA. He elaborated the commonalities and differences among the various agencies. He also explained the role of ICH in harmonizing the drug regulatory affairs between USA, Europe aand Japan. He highlighted the importance of the important documents such as DMF, CTD and e-CTD. He pointed out the punitive actions undertaken by agencies like FDA such as the dreaded 483s.

The second seminar held on 06/02/16 was jointly delivered by Gaurav Kumar and Bhavya on "Regulatory science with emphasis on Bio-clinicals". The speakers elaborated the definitions of drugs as mentioned in WHO and FDC. They spoke about the various aspects involed in Phase 0 to Phase 4 clinical trials. They mentioned the various dimensions of drug discovery. 21 CFR 312-38 was discussed and its importance and relevance explained. There was a video presentation which further explained the intricacies of clinical trials.

The third and fourth seminars were held on 20/02/2016 delivered R Rajendran and Vijayaraghavan. These were the flagship seminars as they involved the co-sponsor of the series, Greenchem Industries Pvt. Ltd CEO, Rajendran- who spoke on the topic "Quality assurance for regulatory affairs". He stressed on the importance on the quality aspects and pointed out the steps to achieve quality. He stressed on achieving reproducibile quality products and explained the ways to achieve it.

Mr. Vijayaraghavan, Head, QA & RA, Green Chem Ind., Bangalore spoke on "Regulatory affairs for herbal medicines". He described complimentary, traditional and herbal medicines. Relevant regulations like D&C act, FSSAI and Biodiversity act were covered by him.

On 27/02/2016, the fifth seminar was delivered by Nitin Bhattad, Senioe Vice President, Mylan Pharmaceuticals. It was an erudite seminar on the topic "CTD & eCTD For Global Regulatory Submissions". He elaborated the pre-requisites for regulatory submissions and commented that it requires a multi-disciplinary effort for regulatory approval. He described the format of CTD and eCTD and also explained its various modules.

Chandramouli R, Head, Department of Quality Assurance, KCP, gave the sixth seminar on "Biowaivers: A Global Regulatory Perspective" and "Developing Stability Studies for Regulatory Submissions" on 05/03/2016. It was a

scholarly presentation which described the provisions for biowaivers. He also explained about the extension potential and risk assessment and objections that can be raised regarding biowaivers.

Premnath Shenoy, ex-Director, Astra Zeneca, gave a remarkable seminar on the topic "Regulatory Pathway for New Drug Approval in India & Multi Regional Clinical Trials - Advantage". It was the seventh seminar in the series held on 12/03/2016. He stressed on the growth of the pharma industry in recent years and cited innovation as the impetus for such a tremendous growth. He highlighted the importance of multi-regional clinical trials and thepotential that India has with regards to it.

Ravi Shyam Madhira, Head-IPR, Jubiliant Organosys, delivered the eighth seminar on 19/03/2016. The topic was "Generic Drugs & Regulatory Affairs". It was an intriguing semnar which delved into the complexity of the regulatory reuirements for ANDA. He eloquently descibed the complexities of FDA Para 4 regulations.The Hatch- Waxman act was also highlighted and its importance in paving the way for developing ANDA was also enunciated.

Mahesh Nosenoor, Head, Department of Pharmacy Practice, KCP, gave the concluding seminar on 02/04/2016 on the topic "Clinical Trials and Regulatory Innovations". He highlighted the innovations in the current regulatory scenario and also explained about the clinical trials.

Summary of CPPA Activities

Sl No	Date	Topic	Speaker / Activity
2014			
1	17 Jan	Visit to GROUP PHARMACEUTICALS - Malur / Bangalore	All MPharm Students + Prof. Mallya
2	18 Jan	Advances in Diagnosis and Imaging of Cancer Impacting Treatment.	Dr. Harsha Doddihial - VP Quintiles, Consulting Oncologist , Bangalore , All PharmD, Final BPharm & Staff
3	24 Jan	Finishing School & Skill Development	All MPharm, Final BPharm, 4 Pharm D
4	25 Jan	IPR Lecture Series By Mr. Ravi Syam Madhira 1	All MPharm, Final BPharm and Staff
5	1st Feb	IPR Lecture Series By Mr. Ravi Syam Madhira 2	All MPharm, Final BPharm and Staff
6	1st Feb	QC, IPQC, GLP, Ranbaxy Issues	Mr.Sarang Athavale, Pharma Industry Consultant, All MPharm, Final BPharm and Staff
7	6t h Feb	Teleradiology, Image Radiology in Clinical Trials and New Drug Development	Dr. Arjun Kalyanpur, CEO, Teleradiology Solutions, Image Core Labs, Bangalore
8	8th Feb	From Research Topic to Publication	Dr. G Jagadeesh, USFDA, Maryland-USA
9	15 Feb	Pharma Industry Visit Tejkamal Pharma,	405 Students and Staff, 3rd Year and Final Year B Pharm
10	17 Feb	Campus Drive/Interview - Presentation for D.Pharm, IV BPharm, PharmD	Religare Wellness, Mr. Rangarajan, Cluster Manager
11	21 Feb	Finishing School Training - Defining Decade, Satya Nadella- Case Study	Final BPharm, MPharm students
12	21 Feb	Life Skills, Personality Development, Motivation, Communication	Mr. MVN Kasyap - Buouyancee - Bangalore
13	22 Feb	IPR in Pharma	Mr.Ravisyam, Jubiliant Organosys, Bangalore
14	22 Feb	Introduction to Marketing & Management to Final BPharm Marketing & Management	Prof. Vinay Rao, Faculty MBA-Krupanidhi
15	21 & 22 Feb	Inaugural Convention of the Indian Association of Colleges of Pharmacy - Advancing Pharmacy Practise In India - Sheraton - Bangalore	Staff & Students of Pharm D
16	28 Feb	Visit to Teleradiology Solutions for Pharm D Internship meeting with Dr. Arjun Kalyanpur and Team	KCP Dr. Raman Dang and Prof. Prakash Mallya
17	1 March	IPR - Patents in Pharma	Mr.Ravisyam, Jubiliant Organosys, Bangalore
18	4 March	Industry Visit - KAPL Injectible Plant, Peenya	Staff & M Pharm Students
19	5 March	Industry Visit - Medopharm Plant, Malur	M Pharm Students
20	6 & 7 March	KDPMA - MSEM Meet, Seminars, Placement Cell and Pharma Exhibition, Hotel Lalit Ashoka, Bangalore	Directors & M Pharm Students
21	10 Mar	SAGAR Pharma Meeting to discuss Artificial Saliva Project Industry - Academia Project	Sagar Pharma - Kiranshanker, Rajesh Bapat, KCP - Dr. RS Thakur, Dr. Raman, Prof. Mallya,

22	19 March	CDSCO/WHO Advances in GMP - PAT Presentation by Chandramouli to CDSCO All India Drug Inspectors - Hotel 37 Crescent, Guest of Honour Prof Prakash Mallya	M/s. Chandramouli R, P V Mallya & Gauvrav Kumar
23	21 March	Valedictory Function Finishing School Batch of 2014, Presentation by 3 Alumini Student and Presently working at ACCENTURE	Final B Pharm & M Pharm Students
24	22 March	Valedictory Function of IPR Lecture Series by Mr. Ravisyam of Jubiliant Organosys, Distribution of Certificates	M Pharm Students
25	16 August	Who Prequalification of Pharmaceuticals - Seminar Dr. Satish V Mallya Health Canada & WHO	All Final Year B Pharm, Pharm D M Pharm and Staff
26	1 - 12 August	Induction Orientation & Softskill Training	All Freshers of KCP
27	25th & 26th August	Workshop on SoftSkills and Personality Development - Ajit Kaikikni / Director Bouyancee / Bangalore	All Final Year B Pharm, Pharm D M Pharm D Pharm
28	25 Aug-6 Sept	Finishing School Training - Prof. P V Mallya	All Final Year B Pharm, Pharm D M Pharm D Pharm
29	2nd Sept	Workshop on Motivation and Stress Management - Dr. R Dayanand / Consultant/Bangalore	All Final Year B Pharm, Pharm D M Pharm D Pharm
30	6 Sept	Peace Education Programme - Jyoti Singh, manisha, Ajitabh, Deepak Dangi.	All Teaching & Non- Teaching Staff
31	13 Sept	Innovation in Herbal Products - Mr. Rajendran CEO, Ravi Rajendran- Director & Team Green Chem/Bangalore	Final B Pharm, M Pharm, Staff
32	8 Nov	Nanotechnology, Vaccines Development Generic Drugs Formulation Development - Dr. Dinesh Shenoy -Director R&D LUPIN Research, Pune	All Staff & M Pharm
33	22 Nov	"Trends & Developments in the Healthcare Industry"- Dr. Harsha Doddihal Co-founder & CEO-Prana Healthcare Enablers Chief Scientific Officer- D Cube Analytics Medical Director - Medsurge	Pharm D, M Pharm, Staff
34	29 Nov	Stem Cell and its Application, Dr. Ramanand Nadig, Diabetalogist, Medical Advisor, Academician	Pharm D, M Pharm, Staff
35	6 Dec	Prof. Anila,Director CLHRD, Mangalore, Competencey Building	II & III B Pharm and II & III Pharm D
36	6 Dec	Prof. Anila,Director CLHRD, Mangalore, Competencey Building and Teachers as a Leader and Effectiveness.	Teaching Faculty KCP and other Campuss Faculty
37	13 Dec	Technical Video Series- Ebola Virus, Organ on Chip, 3D Organ Printing, Virtual Lab Tabletting. - Prof. Mallya	All students

Sl No	Date	Topic	Speaker / Activity
		2015	
38	07 Jan 2015	Full Day Programme on From Campus to Career full day SoftSkill and Life Skills by 2 Alumini MPharm Students-Mr. Kasyap and Ms. Vijaysree	First B Pharm, First M Pharm, First Pharm D, D Pharm & Staff.
39	08 Jan	Organised Full Day Plant Visit for QA MPharm Students and Staff to Himalaya Drug House - Bangalore	QA M Pharm Students with Mr. Chandramouli R
40	22 Jan	Organised Full Day Plant Visit for Final BPharm Students and Staff to Karnataka Antibiotics Pharma Ltd. - Bangalore	Final B Pharm Students with Dr. Kuntal and Ms. Nisha
41	First week	Organised Raw material API from different Pharma Industry for Ketoprofen, Albendazole and Doxorubicin for 3 MPharm Students	
42	21 Feb	Pharmaceutical Plant Design - GMP concepts Mr. G. Satyamurthy Director Himalaya Wellness	B Pharm, M Pharm, Staff
43	7 Mar	Message of Peace - Peace foundation	Far all Staff and Final Year Students
44	14 Mar	Dr. Utkala - Tele Radiology, The Scope of Pharmacy Usual and UnUsual Careers in Pharmacy	All Pharm D, Final B Pharm, M Pharm students.
45	20 Mar	Sanofi India Campus Interview at KCP	All Final B Pharm Students
46	27 Mar	Message of Peace - Peace foundation	All Staff, B Pharm, M Pharm
47	11 April	Big Data Analytics and Business Intelligence - Dr. Venkat Rajgopal	Students & Staff of KCP, MCA, MBA
48	22 Apr	WHO- GMP Workshop on Prequalification c GMP	Profs. P V Mallya, Chandramouli R, Ruchi Agrawal, M Pharm QA Students
49	2 July	Seminar Regulatory Affairs in Pharma - Prof. P V Mallya	All Final Year Students & Staff
50	7 July	KAPL Seminar on GMP Presented by KCP Staff	Mallya, Chandramouli, Kavitha
51	8 July	Pharm D in USA, Dr. Chandra Sekhar, Findlay Univ,	All Final Year Students & Staff
52	13 -20 July	Finishing School	All Final Year Students
53	6 - 8th Aug	Induction Training - Freshers	For All Freshers
54	22 Aug	Seminar Presentation at ASPI - KSPOR, Topic - Is this the End of the Animal Testing era in Drug Discovery "	All KSPOR Delegates.
55	12 Sept	Clinical Research and Career Opportunities	To all Final Year Students
56	5 Dec	A New Wave Healthcare Dynamics - are you Ready for it? - Dr. Harcha Doddihal - Prana Healthcare , Bangalore	Final yr Pharm D, M Pharm, Staff & Students
57	12 Dec	Shri Indu Bhushan (CEO - Steer Pharmaceutical Development Centre, Bangalore) Topic Melt extrusion technology	All Third, Final B Pharm, Alumini, Staff

58	12 Dec	Dr. Ajay Khopade (VP - R&D, Sun Pharma Advanced Research & Discovery Centre, Baroda) Topic Nanotechnology in Pharma, Novel drug delivery systems	All Third, Final B Pharm, Alumini, Staff
59	12 Dec	Dr. Jitendra Kadam (Patent Landscape Analyst,Shell, Bangalore) Topic - Intellectual property management	All Third, Final B Pharm, Alumini, Staff
60	12 Dec	Dr. Dinesh Shenoy (Director - Pharma Research, Lupin Limited, Pune). Topic - Barrier isolator technology - new generation sterile manufacturing	All Third, Final B Pharm, Alumini, Staff
61	12 Dec	Mr. Sudhir Nayak (Head - Metabolics business unit, Biocon, Bangalore) Topic- Recent trends in pharma marketing	All Third, Final B Pharm, Alumini, Staff
62	18 Dec	Dr. Anil Mallya & Dr. Mila Tremblay - PharmD USA - PharmD & Pharmacy Practise in the USA	ALL Pharm D Students & Staff

Sl No	Date	Topic	Speaker / Activity
2016			
63	9 Jan 2016	CPAAT- Divya Madhuri, Narayana Health City, Pharmacotherapeutics	Pharm D, Final B Pharm, M Pharm, Staff
64	27 Jan	Visit to GVK Bio for Discussions on MPharm Projects and Industry -Academia Co-operations	Prof. Mallya, Prof. Bharani, Asst Prof. Arshad
65	30 Jan	Visit by GVK HR and QC to KCP	Mr. Ram. Botta, Mr. Sudheer
66	30 Jan	Regulatory Affairs Seminar Series Jan - Apr 2015, Every Sat. Introduction to RA - Prof. P V Mallya	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
67	6 Feb	Regulatory Affairs Seminar Series Jan - Apr 2015, Mr. Gauvrav & Ms Bhavya, IKON - Clinical Trials in RA	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
68	20 Feb	Regulatory Affairs Seminar Series Jan - Apr 2015, Mr. R Rajendran, Mr. VijayRaghavan - QA Concepts in RA, Herbal RA	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
69	27 Feb	Regulatory Affairs Seminar Series Jan - Apr 2015, Mr. Nitin. Bhattad, Sr. VP Mylan - CTD & e-CTD.	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
70	5 Mar	Regulatory Affairs Seminar Series Jan - Apr 2015, Prof. Chandramouli, Head QA, KCP - Biowaiver, Stability Studies in RA Submissions	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
71	12 Mar	Regulatory Affairs Seminar Series Jan - Apr 2015, Dr. Premnath Shenoy, 1). Regulatory Pathway for New Drug Approvals in India, 2). Multi Regional Clinical Trials - Advantage.	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
72	19 Mar	Regulatory Affairs Seminar Series Jan - Apr 2015, Mr. Ravi Syam Madhira - Generic Drugs and Regulatory Affairs - IPR, Patents etc	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
73	2 Apr	Regulatory Affairs Seminar Series Jan - Apr 2015, Mr. Lakshmeesha,Sr. Scientists, Strides - RA of Container Closure	1 & 2 M Pharm, Final B Pharm, 5 Pharm D, Staff
74	9 Apr	Regulatory Affairs Seminar Series Jan - Apr 2015, Dr. Mahesh Noosnoor, KCP Clinical Trials	1 & 2 MPharm, Final BPharm, 5 PharmD, Staff

2016

EXPRESSIONS

Clinical@KCP

Progress in the Department of Pharmacy Practice

The department of pharmacy practice has been serving for better patient care in Hoskote, Bangalore area, since its inception with a team of dynamic institutional faculties who are comprised of two professors (Dr Mahesh NM, Professor and Head, Dr Ujwala S, Professor and International Clinical Pharmacist from USA) one associate professor (Mrs Rajeshwari R) and three assistant professors (Mrs Bincy V, Teena N and Dr Vidya A) who collaboratively works as one the departments with the practicing physicians from various units of MVJ Medical College and Research Hospital, a 1200 bed multi-specialty hospital located in Bangalore area. In addition, it takes the services of three faculties (Dr Mrudula G, Mrs Deepika B, Veena V) from the department of Pharmacology of our institution.

Pharmacy practice department has organized national level two days conference on the patient safety and pharmacoeconomics in the college premises. In addition, it has organized ten seminar sessions, NSS activities in Bangalore area villages and 80 journal clubs. The department has collaborated with three multi-specialty hospitals such as MVJ Medical College and Research Hospital, Columbia Asia and Teleradiology Solutions. The department strongly believes that the students from Doctor of Pharmacy course can acquire the skills to provide clinical pharmacy and community pharmacy services in both traditional and corporate cultured healthcare environments from such collaborations.

In continuation, the department deputes the interns from doctor of pharmacy course to pursue their internship for three months in other specialized hospitals, which are located across India and abroad. During these two years, our interns have completed their internship in the following hospitals: Vydehi Institute of Medical Sciences, Telerad RxDx, Manipal Hospital, Columbia Asia, Fortis Hospital, Sri Shankara Cancer Hospital and Research Centre, St John

Medical and Hospital, Jayadeva Hospital, Bangalore area; Christian Medical College, Vellore; Pariyaram Medical College, DM WIMS Hospital, Kerala; Continental Hospital, Hyderabad; College of Medical Sciences-Teaching Hospital, Nepal; Erfan hospital, Iran; Sekgoma Memorial Hospital, Serowe and Letsholathebe II Memorial Hospital, South Africa.

The faculties and, the students from fifth and sixth years of the doctor of pharmacy course have attended 20 seminars/workshops that were of national and international level importance across India. There were 19 collaborative pharmacy practice research projects carried out with above mentioned collaborated hospitals till now. From these projects, 20 research papers, including their presentations, and 18 review papers were published in the national and international journals that are having good impact factor. In addition, the department publishes pharmacy practice bulletin known by 'Synergia' quarterly every year, which is widely distributed to many healthcare professionals.

The department provides the clinical and community pharmacy services on daily basis for better patient care. As per our records, 1288 prescriptions were audited and managed 1451 medication related errors at the level of prescribing, administration and dispensing. Twenty three adverse drug reactions were documented. 110 drug information queries were answered. 150 drug-drug interactions were identified and managed. About 5000 patients were educated and counselled about safe medications use. In addition to the community pharmacy services, the monitoring and managing of storage conditions of various emergency medications is done on monthly basis in the nursing stations of various departments beyond monitoring for hemovigilance in blood bank area. The nominated faculties from the department regularly attend the meetings conducted by mortality and pharmacovigilance committee, hospital human ethics committee and pharmacy and therapeutics committee in the hospital.

The department works with the institutional placement committee to place our students in various healthcare organizations such as the multi-specialty hospitals, clinical research organizations and medical writing organizations. During two years of period, our students were placed in the following organizations such as Apollo Hospital, Vydehi Institute of Medical Sciences and Research Hospital, Accenture, St. John's Research Institute, Magna Health care, Synowledge, and IMS Health Private Limited.

2016

EXPRESSIONS

Happenings@KCP

Freshers Day 2014


KRUPANIDHI COLLEGE OF PHARMACY
Bangalore-560035
www.pharmacy.krupanidhi.edu.in

Graduation Day 2014, 2015


Krupanidhi College of Pharmacy
(A NAAC accredited Institution)
Graduation Day 2015

Talents & Sports Week 2014, 2015

Christmas Celebrations 2015

2016

EXPRESSIONS

Creative Canvas

Photos by: Roopesh S K
M Pharm (Quality Assurance)

Today's First Cigarette

Today's first cigarette
But now I regret
You think this is first one of the day
But you don't know which one is last for the day,
The smoke goes upside but it also goes inside
By cigarette you use to do a lot of stunts
But why you are not thinking of your lungs,
You know you can't able to leave this menace
So why are you making this lit,
The day seems to go on
And the cigarette use to burn
They always use to say, its a bad habit
But you never use to learn,
Behind every packet, there is smoking kills
But with your pocket, you always use to deal,
Every hour you use to make it lit
You can leave the world, but you cant leave this menace
Today's first cigarette
But now I regret

Hoshank verma

Realization

Standing on the roof of mind ,
When I look upon the distant sky….
The light upon the black cloud beneath,
Seems blessing in loud.

Knealing to the ground ;
Should we pray when hushed all the sound ,
Bowing down----
Allowing the eternal spring in order to
Brighten us…..

I doubt neither anyone's existence,
Nor any power of love ,
Smelling the agony of erosssion in values..

Vain are the thousand creeds ,worthless as withered
"Rocks of words"….
The steadfast rock of immortality
Being oblivion to thine infinity…

AH!!!!! At last my mind like a frippet ,
Wanders in the allay of disrust.
As if it's realization I can wildly define…..

When I close my eyes
It used to be dark
Every corner pitch black
There could never be noise
For I was the only voice
Now I see colours
Golden daffodil flowers
Now I see you,my lover
Lying beside some river
Without any cover, any cover
The twinkle in your eyes
The dimple on your cheek
The smile on your lips
The scent of your hair
And the song in your heart
Make me live, make me live
The brush of our skins
The rush of the pleasures
The gush of the waters
And the blush in your face
Make me mad, make me mad
I know you are a spell
I know you are a dream
But
I can't wake me up
I can't take me out
Help me forget this 'I'
Or make me forever yours
Finally I have found you
Hope you will find me too.

Someswar Deb
3rd Pharm D

RIGHT
COMMUNICATIONS

solutions to your needs...

#272, 8th Main, 12th Cross, Hombegowda Nagar, Wilson Garden, Bangalore - 560 025.
alxgeet12@gmail.com / aldata2006@gmail.com

Living alongside nature

not at the cost of it

Just another day at your very own slice of the green paradise,
away from the hustle-bustle.

ramya habitat

live green

at Seegehalli, Kadugodi
Bangalore

RAMYA HOLDINGS

Ramya build-tech

#101, SMR Vinay Estate, Outer Ring Road, Banaswadi
Near : Horamavu Jn. Bangalore
www.ramyaholdings.in